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SEX-BIAS IN LUPUS-PRONE (NZBxNZW)F1 MICE: THE INTERPLAY OF
GR1+CD11b+ CELLS, TESTOSTERONE AND GENETICS
ABHISHEK TRIGUNAITE
ABSTRACT

Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disorder
predominantly (9:1) targeting females. Currently, there is no cure for SLE and also there
is a lack of disease predicting biomarkers. The major aim of my research is to determine
the cellular basis of the sex bias in SLE and subsequently facilitate the development of
better therapeutics and biomarkers for the disease. In (NZBxNZW) F1 mice a similar
female bias is observed as in humans and testosterone is shown to be protective against
lupus-like disease development, but the mechanism is not well understood.
We found higher levels of Gr1hiCD11b+ myeloid cells in (NZBxNZW) F1 male mice as
compared to females. Interestingly, Gr1hiCD11b+, as well as Gr1lowCD11b+, cells have
been characterized as granulocytic and monocytic myeloid derived suppressor cells
(MDSCs), respectively. Hence, we hypothesized that - Gr1hiCD11b+ cells suppress B cell
activation and differentiation and protect against lupus-like disease.
We report here that Gr1hiCD11b+ cells from pre-pubertal male and female BWF1
significantly suppress in vitro cytokine-mediated B cell differentiation into plasma cells.
In vivo depletion of Gr1+ cells leads to significantly elevated levels of ANA in male
viii

(NZBxNZW)F1 mice. Additionally, Gr1hiCD11b+ cells are regulated by male sex
hormone.

Our findings also show that Gr1+ cells suppress antibody response to antigen challenge
in (NZB x NZW) F1 male mice through inhibition of T follicular helper (TFH) cells and
germinal center formation. The identification of testosterone dependent immunesuppressive cell population in lupus-prone mice can, in part, explain the protective role of
testosterone in lupus-like disease development.

We also examined the hormone independent contribution of male versus female immune
system in development of lupus like disease in (NZBxNZW)F1 mice. The results of these
studies indicate that the intrinsic auto-immune capabilities of the female (NZBxNZW)F1
hematopoietic cells can override the protective effect of testosterone.

Further studies are required to identify the correlation between immune system
development and sex hormones with specific emphasis on the identification of molecular
targets that may better serve as therapeutic and preventive tools for management of SLE
and provide a better quality of life for people suffering from this disease.
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CHAPTER I

INTRODUCTION

1.1 Introduction to Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE) is a prototypical systemic autoimmune
disease and it affects multiple organs and organ systems throughout the course of the
disease(1). According to the Lupus Foundation of America there are 1.5 million SLE
patients in America and more than 5 million patients worldwide. SLE has been a wellknown immune disorder for more than a hundred years and the first published report of
lupus dates back to 1856. It was later in the nineteenth century that the neoclassical era of
lupus research began when Kaposi first described the systemic nature of the disease in
1872. Till now there is no treatment for SLE.

SLE is characterized by a wide variety of clinical symptoms which may vary from
one individual to another. Such a wide array of symptoms makes the early diagnosis of
SLE and the management of its clinical manifestations very difficult. In order to help in
the early and easy diagnosis of SLE, the American College of Rheumatology has put
1

forth a list of eleven characteristic symptoms of SLE (Table 1.1) and an individual is
considered to have active disease if he or she is positive for any four of the eleven
symptoms. Some of the most common symptoms are- Malar or the Butterfly rash, serum
antibodies against nuclear antigens (dsDNA, histone and chromatin), kidney disorder and
arthritis (1). The American College of Rheumatology has also developed a system for
measuring the severity of the disease known as SLE.

Table 1.1 Clinical symptoms of SLE.

http://www.lupusresearchinstitute.org/lupus-facts/lupus-diagnosis

Disease Activity Index (SLEDAI) which is based on the classical symptoms used for the
diagnosis of SLE. There are certain other disease indexes which are in clinical use to

2

predict long term mortality from lupus like disease. A significant gap in the knowledge of
pathogenesis of SLE is the lack of early disease predicting markers.

1.1.2 Clinical manifestations of SLE
SLE earns the title of a prototypic systemic autoimmune disease from the fact that
the disease can affect a wide array of organ systems. As shown in Table 1.1, SLE can
manifest in many different forms. SLE is a chronic immune disorder characterized by
systemic inflammation leading to renal, dermatological, hematological, cardiovascular,
neuropsychiatric and musculoskeletal disorders (Figure 1.1). The distribution of the
symptoms among the affected population is variable and the extent of organ damage also
varies from patient to patient. SLE proves to be a very complicated disease to treat as it
follows a remitting and relapsing course. Depending on the organ/organ system involved
in the pathology of SLE, it can be fatal in many cases.

3

Figure 1.1 Clinical manifestations of SLE: Various organs and organ systems are
affected in SLE leading to different symptoms and organ damage. Adapted from (2).

One of the prime examples of fatal organ pathologies is the renal failure in SLE patients
due to deposition of IgG immune complexes (IC) within the glomeruli followed by
complement fixation. Among lupus patients SLE is the most common cause of death,
occurring in 34%, followed by infection (22%), cardiovascular disease (16%),
cerebrovascular disease (6%), and cancer (6%) (3). SLE has been shown to be the
4

number one cause of heart failure in young women. To summarize, SLE is a multifaceted disease with various manifestations and organ involvement and can often lead to
fatality.

1.2 Current therapies for SLE and Limitations:
SLE is a very heterogeneous autoimmune disease and presents a challenge to be
clinically treated. Advances in understanding the molecular, genetic, and pathological
aspects of SLE in animal models have improved the treatment regimens in recent times
but there are still many complexities in treating the human disease. Therapies for treating
SLE can be broadly divided into two major categories - 1) Therapies aimed at systemic
immune-suppression and 2) Therapies targeting specific cells and molecules of the
immune system (4).

1.2 (A) Systemic Immunosuppression:
Common treatment regimens for SLE involve the use of nonsteroidal anti-inflammatory
drugs (NSAIDs) such as– naproxen, ibuprofen or, corticosteroids like prednisone targeted
at symptomatic relief during mild flairs of the disease. There have been studies which
show a beneficial effect of anti-malarial drugs used in combination with NSAIDs in
preventing and ameliorating mild manifestations of SLE (5,6). Other more aggressive
therapies for severe SLE manifestations involve stronger and broader spectrum immunesuppressive agents like cyclophosphamide (7), azathioprine, Micophenolate mofetil
(MMF) and methotrexate (8). Most of these drugs target pathways of de novo synthesis
essential for cell division and thereby minimize the generation of new auto-reactive T and
B cells. Some of these drugs are even used in a combinational manner to improve
5

outcomes in patients. For example, MMF and cyclophosphamide used in combination has
been shown to improve renal function in SLE patients (9). However, there are side effects
of these therapies which predominantly manifest in form of leukopenia (decrease in
numbers of circulating leukocytes), gastro-intestinal disorders, oral ulcers, nausea,
vomiting and susceptibility to opportunistic infections (4). Different therapies have
shown various levels of success but there is a lack of a set treatment regime with wide
spread benefits and fewer side effects.

1.2 (B) B cell targeted therapies:
In recent years, the use of monoclonal antibodies against specific immune components,
cytokines and cell types has emerged as alternative therapies for SLE. The advantage of
these therapies over systemic immune-suppression is a higher degree of specificity and
fewer side effects. The most attractive target for cell based therapies over the years has
been B cells as B cells produce pathogenic auto-antibodies leading to most of the
complications seen in SLE patients. Most of the B cell targeted therapies are either aimed
at B cell surface specific antigens for directly eliminating pathogenic B cells or
modulating B cell activation and survival signals. One of the earliest attempts at B cell
therapies came in 1997 when rituximab, a chimeric murine/human monoclonal antibody
(mAb) against B cell surface specific antigen CD20 was approved by the US Food and
Drug Administration (FDA) for use in humans (10,11). In the following years other antiCD20 mAb like atumumab, ocrelizumab and veltuzumab came into existence.
Unfortunately, anti-CD20 mAb either have failed to clear the safety standards to be used
in humans or failed to meet the end point requirements (4).
6

Another approach to B cell based therapies are mAb targeting the B cell receptor (BCR)
or co-stimulatory molecules. Eprauzumab is a mAb against B cell surface specific
antigen CD22 which modulates BCR signaling causing a decrease in B cell numbers by
35-45% (12) and has been shown to have positive results in phase IIb SLE trial.
Abetimus is a mAb which binds to BCR and induces anergy (functional inactivation) of
B cells. However, none of these mAb has not been approved for clinical use due to lack
of sufficient data or efficacy (4,13).

1.2 (C) B cell survival signal targeted therapies:
The last category of B cell directed mAb are aimed at blocking B cell survival signals and
co-stimulatory molecules required for activation and differentiation of B cells into
antibody producing plasma cells. B cell activating factor (BAFF) is a soluble B cell
survival factor that binds to its receptors TACI (transmembrane activator and calciummodulator and cyclophilin-ligand interactor), B-cell maturation antigen and BAFF
receptor. Increased BAFF levels have been associated with disease activity in SLE
patients and have been shown to be correlated to disease severity (14-16). Belimumab is
a humanized mAb against soluble BAFF that prevents the binding of BAFF to its
receptors on B cell surface. Belimumab showed very promising results in clinical trials
and was very well tolerated with a high efficacy. There was a marked decrease in the
total number of B cells, plasmablasts, and IgG, IgA, IgM and IgG anti-ds DNA titers
after treatment with Belimumab (17,18). Belimumab earned the distinction of being the
first FDA approved (2011) therapy for SLE in over 50 years. Another mAb limiting B
cell survival is Atacicept, directed against TACI, the receptor for BAFF and APRIL
7

(another B cell survival signal) leading to reduced serum Ig; however, one side effect is
increased susceptibility to infections in treated individuals (19).

1.2 (D) Co-stimulatory molecule targeted therapies:
Naïve B cells need co-stimulatory signals from T cells to differentiate and proliferate into
plasma cells, making co-stimulatory molecules a viable target for SLE therapy. B cells
need engagement of CD40 cell surface antigen with its ligand CD40 ligand (CD40L) in
order to undergo a germinal center reaction and become antibody secreting plasma cells.
Blocking of the CD40-CD40L pathway was shown to be beneficial in murine models of
lupus (20,21). Additionally, mAb against CD40L have been used in clinical trials of SLE
(19,22) but have not been sufficiently effective. Further studies and trials are required to
understand the exact mechanism of this therapy. Alternatively, blocking of another costimulatory pathway involving B-cell coligands B7-1 and B7-2 with a fusion protein of
extracellular domain of cytotoxic T lymphocyte-associated antigen 4 receptor (CTLA4)
has shown promising results in mouse models of lupus (23). Figure.2 summarizes the
different B cell directed approaches with their targets.

8

Figure 1.2 B cell based therapeutic targets for treatment of SLE. B cell costimulatory
molecules and receptors for the survival factors BAFF and APRIL are shown as well as
cell surface molecules being targeted therapeutically. The therapeutic agents are
identified along with their targets. Adapted from (4).
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1.2 (E) Alternative therapies:
There are studies showing the efficacy of anti-cytokine therapies in treatment of lupus
patients. Neutralizing disease promoting cytokines TNF, IL-1, IL-10, IFN-α and IL-6 has
shown promising results in mouse models of lupus and other autoimmune diseases
(reviewed in detail in (4)). Additionally, there are studies showing the beneficial effect of
blocking specific kinases involved in immune cell function as a target for treating
autoimmune diseases. Specifically, use of small molecule inhibitors of Spleen tyrosine
kinase (Syk), responsible for aberrant T cell signaling in lupus, has been shown to
suppress disease in lupus prone (NZBxNZW) F1 mice (24). There are ongoing clinical
trials for Syk inhibition and it could be a promising therapy for SLE (25).

To summarize, there are various emerging therapeutic targets for treatment of SLE, but
only a few have shown promise with high efficacy and few side effects. The most
common side effect of current therapies is an immune-compromised state of the treated
individuals leaving them highly susceptible to opportunistic infections and poor quality
of life. There is no permanent cure for SLE to date and there is a need to develop more
specific therapies with lesser side effects.

1.3 Overview of autoimmunity and triggering mechanisms:
Classically, autoimmune diseases are defined as the response to non-foreign antigens
mediated by T cells and antibody secretion by B cells. Autoimmunity could manifest in
an organ or tissue specific manner or can affect multiple organs and organ systems.
According to National Institute of Allergy and Infectious Disease (NIAID), there are 80
defined autoimmune diseases and the underlying cause of all the autoimmune disease is a
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dysregulated immune system. Autoimmunity arises from the dysregulation of the
immune system where the body’s defense mechanism goes into uncontrolled overdrive
and attacks self-tissue. It is notable that both the innate (non-specific) and acquired
(specific) branches of the immune system contribute to the development of autoimmunity
with specific cell types playing distinct roles (discussed in more detail in section 1.4).
Hence, it becomes critically important for the immune system to be able to precisely
differentiate between self and non-self-antigens. The importance of identifying self and
non-self was recognized as early as the 1950s when Medawar and colleagues
demonstrated with elegant experimental approaches the very first evidence of immune
tolerance (26). Any breach in immune tolerance can lead to immune-dysregulation and
autoimmunity.

Several theories and factors explain the initiation of autoimmunity resulting from
immune dysregulation. In this section, different triggers of autoimmunity and the
underlying causes will be discussed.

1.3.1 Tolerance to self-antigens:
One of the most fascinating features of the immune system is it’s ability to clearly
distinguish between self-and non-self-tissue, which provides critical cues to immune cells
as when to mount an immune response and when not to. It is appreciated that even after
maintaining a tremendous ability to mount an immune response against an immense
number of foreign antigens; the immune system preserves its specificity and tolerance
towards self-antigens. The most important cell types are equipped with antigen-specific
receptors and have the ability to design their receptors for a wide array of antigens,
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notably T cells and B cells. Most of the time the generation, remodeling and retention of
the T cell receptor (TCR) and BCR and subsequent deletion of self-reactive T cells and B
cells works flawlessly, but there are occasions when the system is leaky and may lead to
non-desirable outcomes in terms of self-reactive T and B cells. T cells and B cells, on
recognizing an antigen and receiving the appropriate co-stimulatory signals, can undergo
clonal expansion and mount an immune response and recruit innate immune cells to take
part in the ongoing immune response. If the T and B cells encounter and recognize a selfantigen, it can lead to deleterious anti-self-immune response that can prove to be very
damaging. Thus it becomes critically important to have safety check points at the
developmental level for elimination of self-reactive T and B cells.

1.3.1 (A) Central tolerance
The process of central tolerance is aimed at eliminating any self-reactive lymphocytes (T
and B cells) at an early developmental stage. Although both T cells and B cells arise from
a common Hematopoietic Stem Cell (HSC), their development takes place in different
lymphoid tissues (27,28). T cell development takes place predominantly in thymus and B
cells undergo development in the bone marrow (BM). Thus, the process of central
tolerance takes place in lymphoid tissues – thymus (T cells) and bone marrow (B cells).

During T cell development in the thymus, T cells undergo a sequential series of
differentiation steps. T cells start as CD4- CD8- (Double negative) which become CD4+
CD8+ (Double positive) and finally mature into CD4+ or CD8+ (Single positive) cells
(29). There are distinct selection processes that the developing T cells must undergo.
Firstly, the double positive (CD4+ CD8+) T cells undergo positive selection. Only the T
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cells that can recognize either peptide/MHC class I or peptide/MHC class II complexes in
the thymic cortex receive a positive signal to continue in the maturation process, while
the remaining T cells with a non-viable TCR are eliminated by the process of apoptosis
(28). After undergoing positive selection for a functional TCR, T cells are either
committed to CD4 or CD8 lineage and later on form the majority of peripheral T cell
population (30). The next step in T cell development, negative selection, is very critical
to the induction of tolerance and involves elimination of T cells bearing a self-reactive
TCR. The most important molecule in negative selection of T cells is the transcription
factor autoimmune regulator (AIRE). AIRE is expressed by medullary thymic epithelial
cells and it controls the expression of numerous self-antigens in medullary thymic
epithelial cells (31,32). These self-antigens are presented to developing T cells in
complex with MHC and T cells with high reactivity to self-antigen/MHC complex are
deleted (33,34). Some T cells with intermediate reactivity to self-antigen/MHC
complexes evade the negative selection process and go on to become regulatory T cells
(Tregs) (described later in section 1.5.2) (32,33). Hence, AIRE plays a very important role
in negative selection of self-reactive T cells, development of Tregs (regulatory T cells)
from some self-reactive T cells and induction of central tolerance. The critical role of
AIRE in maintenance of central T cell tolerance has been shown in both humans and
mouse models where a mutation or deficiency of AIRE leads to severe autoimmune
diseases (35).

B cell central tolerance occurs in BM during B cell development and differentiation. The
central B cell tolerance is mediated either by the deletion of self-reactive B cells or by
receptor editing (36,37). Immature B cells reacting with high affinity to self-antigen
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undergo apoptosis (deletion). This deletion mechanism may be crucial when all receptor
editing options are exhausted (37). B cells express recombination activating genes (Rag)
which are responsible for generation of BCR diversity and receptor editing. After
generation of a viable BCR, immature B cells in the bone marrow cease to express Rag
genes. Immature B cells that encounter multivalent self-antigens revert to pre-B cell-like
phenotype, re-express Rag genes, and induce κ light chain gene rearrangements (if
necessary, λ). New Vκ-Jκ rearrangements, involving upstream V segment and
downstream J segment, delete the original Vκ-Jκ rearrangement that had produced a selfreactive light chain, resulting in newly generated B cells that have a novel light chain that
is no longer reactive to self-antigen. These immature B cells then migrate to the periphery
where they mature into IgM- and IgD-bearing B cells (38-40). The importance of Rag
genes in B cell central tolerance is confirmed by studies showing that mutations in Rag
genes correlate with development of autoimmunity in humans as well as mouse models
(37).

Hence, the process of central tolerance ensures that the auto-reactive T and B cells are
eliminated during development; but still, some of the auto-reactive lymphocytes escape
negative selection and enter the periphery. There are further check points to eliminate
such cells in the periphery but sometimes the breach of central tolerance can lead to
autoimmunity.

1.3.1 (B) Peripheral tolerance:
There are certain immune mechanisms that are in place to deal with the auto-reactive B
and T cells that evade central tolerance check points and enter the periphery. The main
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players in T cell peripheral tolerance are Tregs. Tregs are characterized by the expression of
transcription factor Foxp3 which mediates their immune-suppressive function. Tregs
deprive effector T cells of antigens by forming long-lasting interactions with antigen
presenting dendritic cells (41) and thereby dampen the immune response. Mutations in
Foxp3 gene have been associated with development of autoimmunity in both humans and
mice (35,42).

B cell peripheral tolerance is mediated by induction of anergy, clonal deletion of autoreactive mature B cells, direct suppression by Tregs and clonal ignorance (37). However,
anergy seems to be the most dominant mechanism involved in B cell peripheral tolerance.
Anergy is the process of maintaining auto-reactive B cells in a state of
hyporesponsiveness and making them incapable of reacting to self-antigens. B cell
anergy is mostly mediated by the inability of self-reactive B cells to respond to antigen
coupled to BCR. The most common mechanism for B cell anergy is the lack of costimulation by T cells(43). Defects in silencing auto-reactive B cells in the periphery may
lead to adverse outcomes and autoimmunity.

1.3.2 Mechanisms involving innate immune cells:
Innate immune cells form a very important part of the immune system and play an
instrumental role in generating an appropriate immune response. Innate immune cells
perform various functions like immune surveillance, antigen presentation and clearance
of cellular debris. Dysregulation of innate immunity can lead to aberrant activation of
acquired immune cell subsets and may lead to autoimmunity (44). In this section the role
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of innate immune cells and the underlying mechanisms that may trigger autoimmunity is
discussed.

1.3.2 (A) Dendritic cells and toll like receptors (TLRs):
Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system
and play a crucial role in mounting immune responses. One of the striking features of
DCs is the expression of membrane bound Toll-like receptors (TLRs) which are pattern
recognition receptors (PRRs) capable of responding to both endogenous as well as
exogenous antigens. Currently 13 members of TLR family have been identified, out of
which TLR1 to TLR10 are functional in humans (45). TLRs are capable of recognizing
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) (46). PAMPs are evolutionarily conserved exogenous molecules like
lipopolysaccharide (LPS), peptidoglycan and bacterial and viral nucleic acids. DAMPs on
the other hand are endogenous molecules like heat shock proteins which are released
during tissue injury and cell death (47). TLR3, TLR7, TLR8 and TLR9 are found on the
endosome in DCs (dendritic cells) and recognize viral nucleic acids. Upon binding to
their respective ligands TLRs initiate signaling cascades resulting in DC activation,
upregulation of co-stimulatory molecules (CD80, CD86 and MHCII) and release of proinflammatory cytokines (IFN-α, IL-6) capable of inducing T cell activation (48). It has
been shown in a number of autoimmune diseases, like SLE, type I diabetes and multiple
sclerosis, that over-stimulation of TLRs can lead to abnormal activation of T and B cells,
resulting in autoimmunity (44). Specifically, SLE is characterized by production of antinuclear antibodies and the presence of circulating immune complexes containing DNA
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and RNA. It has been shown that CD32-mediated uptake of these immune complexes
containing DNA and RNA by DCs and the subsequent activation of TLR7 and TLR9
play an important role in pathogenesis of SLE (49,50).

Additionally, DAMPs can also stimulate TLRs and there is a strong possibility that it can
lead to autoimmunity via DC-mediated activation of T and B cells in response to
mechanical tissue injury or necrosis (51).

1.3.2 (B) Defective clearance of cell debris:
As discussed above, circulating immune complexes and DAMPs can lead to overstimulation of DCs, resulting in a break of tolerance and induction of autoimmunity.
Hence, efficient clearance of cell debris is required to make sure that there is not an
excess of TLR stimulants present in the system. There is defective clearance of apoptotic
bodies in mouse models of SLE (52). Also tissue damage resulting in necrosis leads to
abundance of auto-antigens in circulation. Macrophages are the major scavenging cells of
the immune system responsible for clearing cellular debris and apoptotic bodies. It has
been shown in SLE patients that there is defective clearance of apoptotic bodies by
macrophages which in turn causes prolonged exposure to auto-antigens and predisposes
one to auto-antibody production (53).
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1.3.3 Environmental factors:
Autoimmunity could be triggered by environmental factors, including exposure to
microorganisms and diet. Although the exact mechanisms are not well understood, it has
been shown in various animal models that modulation of gut microbiota can alter the
susceptibility to autoimmune diseases (54). The composition of gut microbiota can have
pro-inflammatory or anti-inflammatory effects depending on the host immunological
state (55). In a mouse model of experimental autoimmune encephalomyelitis (EAE)
Bacteroides fragilis polysaccharide A protects from disease by inducing Tregs (56).
Similarly, in (NZWxBXSB)F1 model of lupus, caloric restriction has a protective effect
on lupus-like disease development (57). On the other hand, there is emerging evidence
that engagement of TLRs with gut microbiota DNA can alter the course of autoimmunity
(58). Another interesting theory linking the exposure to microorganisms and development
of autoimmunity is the Hygiene Hypothesis. This theory postulates that the increased
incidence of allergic and autoimmune disorders in developed countries could be an
outcome of a lack of exposure to microorganisms that co-evolved with the human
population. A sudden exposure to such microorganisms may lead to induction of
undesired immunological responses leading to autoimmunity (59). As diet and
composition of gut microbiota go hand in hand it is tough to differentiate the role of each
factor in modulating immunity.

Molecular mimicry has also been associated with induction of autoimmunity as it has
been shown that a lot of viral antigens mimic SLE antigens and can lead to relapse or
even initiation of SLE (60,61). Specifically, an Epstein - Barr virus (EBV) infection has
been associated with increase in SLE incidence. It has been demonstrated that antibodies
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against EBV antigens have cross reactivity to dsDNA which is a major SLE antigen. In
murine models immunized by EBV antigens the production of anti-dsDNA antibodies
was enhanced (62,63). These studies provide a clear link between molecular mimicry and
autoimmunity but further studies are required to elucidate exact mechanism and
correlation to human autoimmune diseases and infections.

Also, the role of genetics cannot be overlooked in shaping the immune system and
susceptibility to autoimmunity (discussed in detail in section 1.6).

To summarize, autoimmunity is a very complex process and the exact underlying
mechanisms triggering autoimmunity are not clear. An autoimmune disease could
manifest as a result of any of the above mentioned triggers or can be an outcome of a
combination of multiple factors.

1.4 Sex Bias in SLE:
The majority of the systemic autoimmune diseases have a strong female bias but the
actual basis of the sex bias in autoimmunity is not well understood. In fact studies have
shown that of all the autoimmune-disease affected individuals, more than 75% are
females (64,65). SLE has a strong female bias, with a female to male ratio of 9:1 in
human population. SLE is most prevalent in young women during the child bearing years
(15-45years) and the incidence of the disease goes down in menopausal women (66). It is
to be noted that in prepubescent years there is a female bias in SLE but the ratio of female
to male patients is 3:1. Although fewer men develop SLE, male patients present with a
more severe form of the disease involving a higher incidence of seizures, more severe
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renal disease as well as cardiorespiratory disorders as compared to female patients
(66,67). Over all this suggests that the development and pathogenesis of SLE is different
between males and females.

1.4.1 Mouse models to study SLE:
Many murine models of SLE exist and some of them show a similar sex bias in disease
development as observed in humans. Commonly used mouse models of lupus are - (NZB
x NZW)F1 hybrid, B6.Nba2, B6.Sle123, MRL/lpr, and BSXB/Yaa (68) . All these mouse strains
spontaneously develop a lupus like disease and mimic a variety of symptoms present in human
SLE. One of the widely studied spontaneous murine models of lupus, the (NZBxNZW)

F1 mouse has a strong female bias to the development of lupus-like disease. These mice
are genetically susceptible to develop a lupus like disease where 100% of the females
develop disease by 12 months of age whereas only 30% of male mice develop disease
(69). Interestingly, in the (NZBxNZW) F1 mouse model, lupus like disease is
characterized by elevated levels of circulating serum autoantibodies to nuclear antigens
chromatin, histone and dsDNA. These mice also develop renal disease marked by IgG
immune complex (Ig-IC) deposition within the kidney glomeruli. Glomerulonephritis and
the extent of renal damage can be measured in terms of proteinuria (70,71).
(NZBxNZW)F1 is a spontaneous and multigenetic model of SLE and closely resembles
the sex bias observed in humans. Additionally, (NZBxNZW) F1 mice mimic most of the
important symptoms of human disease which makes it a valuable tool to study lupus. All
the research described in this thesis has been performed using the (NZBxNZW) F1
mouse model of lupus.
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1.4.2 Role of sex hormones in gender bias in SLE:
The fact that 9 out of 10 SLE patients are female in their child bearing years and that the
incidence of disease is lower in prepubescent and menopausal women strongly suggests
the role of female sex hormones in the pathophysiology of SLE. The incidence of SLE is
the highest in women during the time of their life when they are exposed to maximum
levels of female sex hormones. Also the noticeable lower prevalence of SLE in male
populations indicate that there is a protective role of androgens in the development of
SLE.

1.4.2(A) Pathological role of Estrogen in SLE:
Early studies performed on (NZBxNZW) F1 mice showed that ovariectomy of female
(NZBxNZW) F1 mice protected them from developing a lupus like disease and treatment
of castrated male mice with estrogen leads to severe lupus-like disease (72,73). B cells
are central in SLE as they produce auto antibodies leading to disease pathology. Several
studies have documented the role of estrogen on B cell development, differentiation and
tolerance. It has been shown in a estrogen driven model of lupus that elevated levels of
estrogen lower the threshold for negative selection by up regulating Bcl-2 (anti-apoptotic
molecule) during B cell development, breaching central tolerance of B cells, thereby
increasing the number of auto reactive B cells in the periphery (74,75). Additionally
estrogen can enhance the maturation of B cells (76) and selectively impair the negative
selection of high-affinity DNA reactive B cells leading to higher numbers of mature
DNA reactive B cells (77). Estrogen has also been shown to increase the expression of
the co-stimulatory molecule CD40L on T cells and B cells from lupus patients (78,79).
Hence, estrogen not only directly pushes B cells towards a pathogenic phenotype, but
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also aids B cell differentiation and maturation via up regulating co-stimulatory signal
from T cells.

1.4.2(B) Protective role of testosterone in SLE:
Testosterone has a broad immune-suppressive effect on the immune system as is evident
from the fact that males are more susceptible to infections and cancers as compared to
females (80). Specifically, in SLE the protective role of testosterone was clearly
demonstrated in 1970s by Talal and colleagues. In sex hormone manipulation studies in
lupus prone (NZBxNZW) F1 mice it was shown that male mice were protected from
disease development by the presence of testosterone as castration resulted in the
development of lupus-like disease symptoms similar to those observed in age-matched
female (NZBxNZW) F1 mice. Even more interesting, female (NZBxNZW) F1 mice with
severe disease showed reduced disease severity and prolonged survival upon treatment
with testosterone (72,73,81). The protective role of testosterone is not only limited to
SLE but it has been shown to play a protective role in other autoimmune diseases likeEAE and rheumatoid arthritis (RA) (82,83). Likewise, testosterone-replacement therapy
of Klinefelter’s Syndrome patients led to decreased serum antibody and cytokine levels
and decreased T and B cell levels (84). It has been documented that SLE patients have
lower circulating levels of testosterone and higher aromatase activity which can convert
testosterone to estrogen (85).

It is evident that male and female sex hormones play a significant role in sexual
dimorphism observed in SLE and other autoimmune diseases. Estrogen drives
autoimmunity while testosterone is protective. To a large extent the disease driving
22

mechanisms and effects of estrogen on immune cells are well understood. But there is
gap in knowledge for many years as to how testosterone exerts a protective effect in SLE.
The mechanisms of testosterone driven protection from SLE are not well understood and
have been underexplored.

1.5 Key cellular components in lupus:

1.5.1 Role of B cells:
Most of the organ damage seen in lupus is mediated by auto-antibodies produced by B
cells, so B cells can be called the drivers of lupus pathogenesis (86). B cell hyperactivity
is a hallmark of SLE. Naïve B cells from mouse models of SLE have been shown to
respond very strongly to BCR stimulation as compared to naïve B cells from nonautoimmune mouse strains (87). B cells from lupus patients have a high expression of
CD40L, generally expressed only by T cells, indicating that lupus B cells can activate
other naïve B cells (88). Moreover, the emerging role of B cells as cytokine producing
and antigen presenting cells can also contribute to their role in lupus progression (89).
Additionally, there is an accumulation of auto-reactive B cells in the marginal zones of
spleens in mouse models of SLE (89,90). These auto-reactive B cells have a low
threshold for tolerance and can play a prominent role in initiating autoimmunity (90). A
regulatory B cell subset producing IL-10 (Bregs) has been identified but the role of this B
cell subset is not well understood in the development of SLE (91,92).
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1.5.2 Role of pDCs:
Plasmacytoid DCs (pDCs) were first identified as CD11c- immature DCs in human
peripheral blood (93). As compared with conventional DCs, pDCs express lower levels of
MHCII, lower levels of co-stimulatory molecules and a reduced ability to stimulate T
cells (93). In contrast, pDCs are the dominant interferon-producing cells in response to
most viral infections. In fact pDCs have been shown to produce 200-1000 times more
IFN-α, in response to microbial challenge, compared to any other cell type, conferring
these cells an important role in anti-viral and anti-tumor immune responses (94,95).
There have been several studies showing the crucial role of IFN-α in development of
lupus like disease in mouse models. In fact IFN-α has been associated with development
of auto-antibodies and IFN-α receptor deficiency has been shown to protect lupus prone
mice from developing disease (96,97). There is an elevated level of circulating IFN-α in
human SLE patients which correlates with disease severity and anti-dsDNA antibodies
(98,99). Also, peripheral blood cells from SLE patients present with a typical gene
expression pattern known as an “Interferon Signature” where IFN-α inducible genes are
upregulated (100,101). A recent study showed that depletion of IFN-α producing pDCs in
lupus prone B6.Nba2 mice leads to reduced levels of anti-nuclear auto-antibodies (102).
Since, pDCs are dominant producers of IFN-α, we can speculate that they may play a
pivotal role in SLE pathogenesis.

1.5.3 Role of neutrophils:
Neutrophils are innate immune cells of myeloid origin and arise from the common
myeloid progenitor (CMP) in the BM in response to specific stimuli including both
cytokines and growth factors (103). Neutrophils are the most abundant circulating
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immune cells and form the first line of defense against microbial and fungal infections.
These cells are short-lived and contain granules rich in anti-microbial proteins to kill
invading pathogens (104). The disease driving role of neutrophils in SLE has been
extensively studied and well documented (105), but in recent years there have been
studies exploring the anti-inflammatory properties of neutrophils in SLE and a variety of
other autoimmune disorders (106). In the following section, the pro and antiinflammatory role of neutrophils will be discussed in detail.

1.5.3 (A) Pro-inflammatory role of neutrophils:
The role of neutrophils in driving SLE has become more evident in recent years and
various neutrophil driven phenomena have come to light that can aid SLE progression.
Neutrophils are potent producers of cytokines that can modulate both T cell and B cell
function and differentiation. Neutrophils produce IL-6, BAFF and APRIL, powerful B
cell regulators associated with B cell development and antibody production (106). IL-6
manipulation has been shown to affect lupus pathogenesis in mouse models of SLE (107109). BAFF is a B cell survival signal and it has been reported that neutrophil derived
BAFF leads to elevated T and B cell responses in lupus prone mice (110). APRIL is a
plasma cell survival signal and BM neutrophils from lupus patients produce APRIL
(111). Thus, neutrophil derived cytokines can aid B cell differentiation and development
at an early stage and prolong survival of antibody producing plasma cells. Another
important cytokine in SLE pathogenesis is IL-21, which is required for GC formation and
antibody production (112). Neutrophils can produce IL-21 under chronic inflammatory
conditions and lead to T cell independent B cell activation and differentiation in SLE
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(113). Finally, neutrophils can also produce IL-17A which has been implicated in
development of SLE and other autoimmune disease (114).

Another interesting area of emerging research regarding the role of neutrophils in
pathogenesis of SLE is NETosis. NETosis is a specialized process of neutrophil death
where neutrophils form NETs (neutrophil extracellular traps) to trap pathogens and
subsequently undergo death (115,116). NETs are loaded with anti-microbial proteins like
myeloperoxidase (MPO) and LL37, along with histones and free DNA and are shown to
induce IFN-α (key cytokine in SLE discussed in section 1.6) production via TLR9
crosslinking in pDCs (117). Recently, in SLE patients a subset of neutrophils termed as
low density granulocytes (LDGs) have been shown to undergo spontaneous NETosis in
vitro and produce IFN-α (118).

1.5.3 (B) Anti-inflammatory/immunosuppressive role of neutrophils:
The very first evidence for the existence of the anti-inflammatory neutrophils came from
cancer studies. Ly6-G+ and Ly6-C+ immature myeloid cells were shown to infiltrate
tumors and to suppress anti-tumor T cell responses in cancer patients (119). Since then
there have been numerous studies defining the immunosuppressive function and
mechanisms of these neutrophil like cells. Such cells have been named myeloid derived
suppressor cells or MDSCs. The regulatory functions of MDSCs and the identification of
MDSCs as potent immunosuppressive cells were first established in cancer models,
where the cells act to suppress T cell mediated anti-tumor responses (reviewed in detail
(120)). MDSCs are further divided into two different categories based on cell surface
marker

expression-

Gr-1highLy-6G+CD11b+(granulocytic
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MDSCs)

or

Gr-1lowLy-

6C+CD11b+(monocytic MDSCs) (121) (Figure 1.3). MDSC subsets isolated from tumors
have been shown to use reactive oxygen species (ROS), inducible nitric oxide synthase
(iNOS), and TGF-beta as their main mechanisms of T cell suppression (121-124). The
role of MDSCs in autoimmune diseases is currently emerging and it has already been
shown in EAE and type I diabetes that MDSCs can suppress autoimmunity and alleviate
disease symptoms (125,126).

Monocytic
MDSCs

Granulocytic
MDSCs

Figure 1.3 The pathways of MDCS development and differentiation in cancer.
MDSCs develop from the CMP (common myeloid progenitor) in BM. MDSCs are
classified as Monocytic MDSCs (Gr1low CD11b+) and Granulocytic (Gr1
Adapted from (120).
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high

CD11b+).

These studies encouraged us to explore the role of MDSCs like cells in lupus prone (NZB
x NZW) F1 mice. Interestingly, we found elevated levels of Gr-1highLy- 6G+CD11b+ and
Gr-1lowLy-6C+CD11b+ MDSC like cells in lupus prone male (NZB x NZW) F1 mice as
compared to female (NZB x NZW) F1 mice and hypothesized that – Higher of levels of
Gr-1highLy- 6G+CD11b+ and Gr-1lowLy-6C+CD11b+ MDSC like cells in lupus prone
male (NZB x NZW) F1mice may protect them from development of lupus like
disease. The results of the studies performed to test this hypothesis are discussed in detail
in ChapterII (Gr-1highCD11b+ Cells Suppress B cell Differentiation and Lupus-like
Disease in Lupus-Prone Male Mice; Published in Arthritis and Rheumatism, 2013).

1.5.4 Role of T cells:
T cells are indispensable for driving lupus like disease as T cells help is essential for
formation of germinal centers and B cell differentiation into antibody secreting plasma
cells (127,128). There are different functions associated with the various T cell subsets in
the pathogenesis of SLE. This section will discuss the role of each T cell population in
SLE.

1.5.4 (A) Role of TH17 cells:
TH17 cells are characterized by the expression of the transcription factor ROR-γt and the
production of the pro-inflammatory cytokines IL-17, IL-21, IL-22, and IL-6 (129,130).
TH17 cells play an important role in protection against bacterial and fungal infections and
clearance of pathogens (131,132). TH17 cells have also been associated with the
induction and development of autoimmune diseases, including SLE (114,132-134).
Several studies have shown an increase in TH17 cells in both murine models of lupus as
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well as in patients with SLE. Additionally, the increased circulation of CD4+ TH17 cells
correlates with disease activity in patients with SLE (131,135). The main cytokine
produced by TH17 cells, IL-17, works in accordance with BAFF, promoting B cell
proliferation and differentiation into antibody secreting cells, and ultimately the
production of autoantibodies (136). The TH17 polarizing cytokine IL-6 is also increased
in patients with SLE as opposed to healthy controls, and studies have shown that IL-6
plays a role in B-cell hyperactivity and autoantibody production (131,135,137).

A

dichotomy exists between levels of TH1 and TH17 in patients of SLE. The TH1 cytokine,
IFN-γ is shown to suppress TH17 differentiation, and a deregulation between TH17:TH1
balance has been observed in patients with SLE (131,135). In support of this, a
significant down-regulation of IFN-γ and reduced levels of TH1 cells have been reported
in patients with SLE (131,135,138). However, increased levels of IFN-γ were observed
in patients with active SLE (135). Overall, TH17 cells play a disease driving role in SLE
by mostly promoting auto-antibody producing B cells.

1.5.4 (B) Role of TH1 cells:
TH1 cells play a crucial role in protecting an individual from infections by bacteria, fungi,
and viruses (132,139-141). The pro-inflammatory cytokines produced by these cells,
IFNγ and TNFα/β, stimulate innate and cell-mediated responses, resulting in the
clearance of pathogens (142). TH1 cells however have been associated with autoimmune
diseases such as type I diabetes and RA (143,144). Studies have shown that both levels
of TH1 cells as well as levels of IFN-γ are decreased in patients with SLE, leading to an
increase in TH17 cells and a propensity towards disease (131,135,138). Other studies have
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shown that, among patients with lupus nephritis however, a predominance of TH1 cells is
observed and promotes renal inflammation (145). Thus, the role of TH1 cells in the
progression of lupus is not clear.

1.5.4 (C) Role of TH2 cells:
The function of TH2 cells is associated with activating humoral immunity and promoting
IgG1 and IgE class switching, protecting against extracellular pathogens such as
helminthes (132,146).

TH2 cells secrete IL-4, IL-5, IL-6 as well as the pleiotropic

cytokine IL-10. Interleukin-10 is best known for its anti-inflammatory effects and
enhancing the survival and differentiation of B cells (147,148). Patients with SLE have
been shown to have increased plasma levels of IL-10 (135,137). IL-10 has been shown to
be over produced by B cells and monocytes in patients with SLE (149), and may act in an
autocrine or paracrine fashion resulting in B cell hyperactivity. Levels of plasma IL-10
were also shown to correlate with overall disease activity (135). The effects of IL-10 on
lupus pathogenesis may result from increased TLR-9 expression on B cells, which has
been shown to correlate with disease activity and anti-nuclear autoantibodies in SLE
patients (150).

1.5.4 (D) Role of Tregs:
T-regulatory cell (T-regs) are characterized by the expression of the transcription factor
FoxP3 and surface markers CD4+CD25+. T-regs are known to produce the cytokines
TGF-β and IL-10 (132). It has been speculated that T-regs suppress autoreactive effector
T cells and that a decrease in levels of T-regs may result in the development of
autoimmune disease; however the role of T-regs in lupus is not fully understood (138).
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Studies conducted with SLE patients showed a decrease in TGF-β levels both in plasma
and within the periphery (135) . The increased presence of IL-6 within these patients may
be inhibiting the induction of T-regs and instead promoting TH17 differentiation and
lupus initiation (135).

1.5.4 (E) Role of TFH:
T follicular helper cells (TFH) are a pro-inflammatory subset of CD4+ T cells that are
required for germinal center (GC) formation and plasma cell differentiation. Germinal
centers are the sites within secondary lymphoid tissue (spleen and lymph node) where
mature B cells interact with T cells and undergo proliferation and differentiation, affinity
maturation and class switching to generate a T cell dependent antibody response. The
formation of GCs (Figure 1.4) is central to mounting an antibody mediated immune
response and generation of long lived plasma cells (reviewed in detail in (151). TFH cells
are defined by the production of IL-21 which promotes GC formation and B cell
differentiation, expression of the chemokine receptor CXCR5 which allows them to
relocate to B cell follicles, expression of the transcription factor Bcl-6 and the
costimulatory receptor ICOS, and high expression of the inhibitory receptor PD-1 (152).
Within the GC, TFH cells promote somatic hypermutation and selection of high-affinity B
cells followed by differentiation of long-lived memory or plasma cells. This process
ensured the development of long-lived humoral immunity (112). TFH cells have been
shown to be dysregulated in SLE patients (153,154). Increased levels of TFH cells caused
by TFH dysfunction results in increased GC formation and differentiation of B cells into
antibody producing cells, leading to the production of autoantibodies (154,155).
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Figure 1.4 The role of TFH cells in GC formation. Adapted from (152).

Since, T cells and specifically TFH cells play a crucial role in pathogenesis of lupus via
GC formation and generation of antibody producing plasma cells, based on our earlier
findings, we examined the role of Gr-1+CD11b+ MDSCs like cells on T cell independent
and T cell dependent antibody responses in lupus prone (NZB x NZW) F1 mice. The
findings of this study are discussed in detail in Chapter III (Gr1+ Cells Suppress TDependent Antibody Responses in (NZB x NZW) F1 Male Mice through Inhibition
of T Follicular Helper Cells and Germinal Center Formation; Published in The
Journal of Immunology, 2014).
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1.6. The role of genetic factors on SLE:
Like many other systemic autoimmune diseases SLE has a very strong female bias and
the role of genetics cannot be overlooked in the incidence of SLE. There are strong data
from mouse and human studies which strongly point towards an important role of
genetics in the incidence and progression of SLE. One of the major factors is the dosage
compensation effect of the X chromosome where females (XX karyotype) and
individuals affected by Klinefelter syndrome (XXY karyotype) are 10 times more
susceptible to SLE as compared to males (XY karyotype) (156). The role of the X
chromosome in SLE development was elegantly shown in the pristane induced lupus
model using Sry-transgenic mice. It was shown that male castrated XXSry mice were
more susceptible to lupus as compared to XY-Sry mice (157). Similarly, BXSB.Yaa mice
containing Yaa (Y-linked autoimmune accelerator) which is a 4-megabase translocation
of the distal end of X chromosome onto Y chromosome have exacerbated lupus like
disease (158-160). One of the genes expressed on the distal end of the X chromosome is
TLR7 and it has been strongly associated with susceptibility to lupus (161). Some of the
most detailed insights into the genetics of SLE have come from the New Zealand Black
(NZB) and New Zealand White (NZW) mixed strains (NZM). The (NZB x NZW)F1
hybrid develops a lupus like disease with a strong female bias displaying characteristic
features such as - anti-nuclear antibodies and glomerulonephritis (70), while none of the
parent strains develop full blown disease (162). Detailed studies lead to the identification
of two separate susceptibility loci in the NZM mice, Sle1 (located on chromosome 1) and
Sle2 (located on chromosome 4) (163,164). Congenic mice expressing either the Sle1 or
Sle2 locus have specific symptoms but none of them develop renal disease whereas
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combining Sle1 and Sle2 resulted in glomerulonephritis and enhanced mortality (160).
This is a strong indication of the complex multigenetic nature of lupus like disease in
mice. Also these studies show that the genetics involved in pathogenesis of lupus is
autosomal as well as sex chromosome linked. Additionally, Pre-B cell lines from fetal
livers (FLs) of lupus prone (NZB x NZW)F1 mice transferred lupus-like disease to SCID
(Severe combined immuneodeficiency) mice but it is not known if the cell lines were of
male or female origin (165).

It is evident that sex hormones (discussed in 1.4.2) and genetics play an important role in
the incidence of lupus-like disease and its severity, but the relative contribution of each
factor is not well understood. In order to address this issue we utilized a mixed BM
chimera system to delineate the role of sex hormones and genetics/intrinsic hematopoietic
properties of immune cells in the development of lupus like disease in (NZB x NZW)F1
mice. The results of this study are discussed in detail in Chapter IV (Intrinsic
autoimmune capacities of hematopoietic cells from female New Zealand hybrid
mice; Published in Genes and Immunity, 2014).
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CHAPTER II
GR-1HIGHCD11B+ CELLS SUPPRESS B CELL DIFFERENTIATION AND LUPUS
LIKE DISEASE IN LUPUS PRONE MALE MICE
Abstract
Objective. Systemic lupus erythematosus (SLE) develops much more readily in females
than in males. Previous research has focused primarily on identifying mechanisms
pertinent to the pathology in females. The aim of the current study was to delineate active
protective mechanisms in males. We present evidence of a new male-associated
mechanism of protection against the development of lupus-like disease in lupus-prone

(NZB x NZW) F1 mice.

Methods. We identified previously uncharacterized cellular and functional differences in
myeloid cells between male and female (NZB x NZW)F1 mice, with the use of flow
cytometry, confocal imaging, in vivo antibody-mediated depletion, and in vitro cell
coculture assays.
Results. A population of Gr-1highLy-6G+CD11b+ myeloid cells was found to be
constitutively increased in male (NZB x NZW)F1 mice as compared with female mice
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and was regulated by testosterone. The cells were located adjacent to spleen B cell
follicles in vivo and were found to directly inhibit cytokine-induced differentiation of
naive B cells into antibody-secreting cells in vitro. Most notably, treatment with anti–Gr1–depleting

antibodies

increased

the

spontaneous

production

of

antinuclear

autoantibodies in male (NZB x NZW)F1 mice, while a similar approach in female mice
had no effect on disease development.

Conclusion. Male lupus-prone (NZB x NZW)F1 mice harbor elevated levels of a
population of myeloid cells with pronounced immunosuppressive capacities that
specifically target B cells and the production of antibodies in vivo. We suggest that these
cells represent a male-driven inhibitory mechanism involved in the control of B cell
pathogenesis, delaying (or preventing) lupus-like disease development in otherwise
genetically predisposed male (NZB x NZW)F1 mice.

2.1 Introduction
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disorder.
The disease is characterized by elevated levels of antinuclear antibodies (ANAs) and
cellular infiltration of various organs, including the skin, heart, and kidney(1). Like most
systemic autoimmune diseases, SLE predominantly affects women. The female-to-male
ratio of newly diagnosed patients reaches 9:1 between the ages of 15 years and 45 years
(66,67). This coincides with the years when female sex hormones are the most active, and
thus, much research has focused on elucidating the role of female sex hormones
(particularly estrogen) in SLE. For example, it is well accepted that elevated levels of
estrogens affect B lymphocyte selection processes by altering the threshold for negative
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selection, thereby allowing more self-reactive B cells to survive and differentiate
(74,166). Testosterone, on the other hand, is believed to be protective, based on mouse
studies (70,72,73,167) and clinical data from SLE patients treated with testosterone or the
adrenal steroid dehydroepiandrosterone (168-170). Still, the target of regulation and the
specific mechanism of protection mediated by testosterone remain unidentified.
In some animal models of SLE, female predominance is similarly observed. One such
model is the (NZB X NZW) F1 hybrid mouse. Within 1 year of birth, 100% of female
(NZB X NZW) F1 mice develop a lupus-like disease that is characterized by increased
levels of anti-chromatin, anti-histone, and IgG anti–double-stranded DNA (anti-dsDNA)
autoantibodies, as well as glomerulonephritis, IgG immune complex (IC) deposition
within the kidney glomeruli followed by complement fixation, and renal disease
(proteinuria) (69-71). In contrast, only ~30% of male (NZB x NZW)F1 mice develop
disease within this time period. In fact, the maximum incidence in male (NZB X
NZW)F1 mice reaches only ~65% (69). We used this model to pursue potent naturally
occurring immunosuppressive mechanisms that actively protect genetically susceptible
males against the development of lupus-like disease.
In non-autoimmune individuals, self-reactive cells are kept in check by both central and
peripheral mechanisms of tolerance. The immune regulatory network consists of
regulatory cells of many origins. The best known component is the regulatory T cell,
which has been extensively studied both in mouse models of lupus and in SLE patients
(for review, see refs. (171,172). Newer members of the regulatory family include
regulatory interleukin-10 (IL-10)–producing B cells and myeloid-derived suppressor cells
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(MDSCs), both of which have been studied in only a few models of lupus (92,173,174).
MDSCs represent a heterogeneous pool of immature myeloid cells that are generated in
the bone marrow and are released under inflammatory conditions (175,176). MDSCs
have been extensively studied under tumorigenic conditions, and antibody-mediated
depletion of MDSCs supports tumor eradication in tumor bearing mice. Similarly,
treatment of renal cell carcinoma patients with a receptor tyrosine kinase inhibitor
(sunitinib) reduces the numbers of MDSCs and diminishes tumor progression (177-179).
We report herein the identification of a population of immunosuppressive myeloid cells
(Gr-1highLy- 6G+CD11b+) that were significantly up-regulated in a testosterone-dependent
manner in male mice. Antibody mediated depletion of the cells in male, but not female,
mice resulted in elevated autoantibody production and IgG IC deposition. Accordingly,
we show that (Gr-1highLy-6G+CD11b+) cells from male and female mice use different
mechanisms of suppression in vitro and that cells from female, but not male, mice lose
their suppressive capability with aging. We suggest that this population of myeloidderived cells is heterogeneous and differentially regulated in males and females, resulting
in active protection against the development of spontaneous autoimmunity in otherwise
genetically predisposed males. These findings offer a significant new therapeutic target
for lupus patients.
2.2 Materials and Methods

2.2.1 Mice and cells
Male and female (NZB X NZW)F1 mice (3 weeks old) were obtained from JAX Mice
(The Jackson Laboratory) and were maintained at the Biological Resource Unit at Lerner
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Research Institute, Cleveland Clinic. Castrated male (NZB X NZW)F1 mice (3 weeks
old) were also obtained from JAX Mice. Slow-release pellets containing 12.5 mg or 25
mg of 5α-dihydrotestosterone (Innovative Research of America) were inserted
subcutaneously in the neck region of castrated mice that had been anesthetized with
isoflurane (Terrell; Primal Critical Care). Reconstitution was considered successful when
levels of serum testosterone had equalized to the levels in age-matched unmanipulated
male mice. There were no statistical differences in the levels of testosterone present in
mice receiving the 12.5-mg or the 25-mg pellets. Five weeks later, mice were killed and
examined. All mouse experiments were approved by the local Institutional Animal Care
and Use Committee.
Antibody-treated mice were injected intraperitoneally every 3 days for 8 weeks with 500
μg of anti–Gr-1 antibody (RB6-8C5 monoclonal antibody), 500 μg of rat IgG, or sterile
filtered 1X phosphate buffered saline (PBS), each in a total volume of 200 μl. For in vitro
studies, Gr-1highCD11b+, Gr-1lowCD11b+, and B220highCD19high cells were isolated by
flow-based cell sorting using a FACSAria I (BD Biosciences). All sorted cells were
confirmed to be negative for CD3 and CD11c expression. Cytospin was performed using
Cytology Funnel disposable sample chambers (Fisher HealthCare), Shandon Cytoslides
(Thermo Scientific), and a Cytology Cytospin 2 centrifuge (Shandon). Cells were stained
with hematoxylin and eosin (Newcomer Supply).

2.2.2 Flow cytometry
Flow cytometry was performed using either a FACSCalibur or a FACSAria I instrument,
and all analyses were done using FlowJo version 9.5.2 software (all from BD
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Biosciences). Antibodies with the following specificities were used for all analyses: CD3,
CD11b, CD11c, CD19, CD21, CD23, B220 (CD45R), CD49d, F4/80, Ly-6C, CD16/32,
Gr-1 (Ly-6C/6G), IgM, and IgD (all from eBioscience). Anti– Ly-6G antibody was
obtained from Miltenyi Biotec and anti- CXCR2 antibody from R&D Systems.

2.2.3 Immunostaining
For

histological

analyses,

half

kidneys

were

harvested

and

fixed

in

4%

paraformaldehyde. Glomerular structure and inflammatory cells were determined on two
5μm sections 30μm apart after Hematoxylin/Eosin staining (Newcomer Supply). The
number of mesangial cells/glomerulus was determined in a blinded fashion. For detection
of IgG, IgM and complement factor 3 (C3), half kidneys were quick-frozen in OCT™
and 5μm sections were prepared and stained using TexasRed-conjugated anti-mouse IgG
(Invitrogen) or anti-mouse IgM antibodies (Southern Biotech) alongside FITCconjugated anti-mouse C3 specific antibodies (ICL, inc.). Images were collected using an
HC Plan Apo 20x/0.7NA objective lens on a Leica DMR upright microscope (Leica
Microsytems) equipped with a Retiga EXi Cooled CCD Camera (QImaging). Depositions
were quantified using ImageProJ Plus software (Media Cybernetics) and are given as
density (green or red) per area (glomerulus). Five to eight glomeruli were measured per
sample and data are presented as the mean ± SEM per 8 treatment group. Detection of
Gr1-expressing cells within spleens of male and female (NZB x NZW)F1 mice were
done using FITC-conjugated anti-Gr1 antibody (eBiosciences), APC-conjugated antiCD11b antibody, biotin-conjugated MOMA-1 antibody, APC or biotin-conjugated antiB220 antibody (eBiosciences), and Alexa Fluor 568-conjugated streptavidin on 5 μm
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frozen sections. Confocal images were obtained using a Leica TCS-SP-AOBS Spectral
Laser Scanning Confocal Microscope (Leica Microsystems) and analyzed using Leica
Confocal Software (Leica Microsystems).

2.2.4 Elution of antibodies from kidneys
Total antibodies were eluted from frozen kidneys. Briefly, kidneys were thawed, cut into
smaller pieces (<1 mm diameter) and added Urea-Glycine buffer (0.5M Urea, 0.15M
glycine, pH 2.8) at a 1:5 weight/volume ratio. Then samples were sonicated 5 cycles of
30 sec./30 sec. rest, and left ON at 4°C. Supernatants were harvested after centrifugation
and applied to Amicon Ultra 3K centrifugal filters (EMD Millipore, MA). All kidneys
were weighed before elution and the final elution volume was determined. Eluted
antibodies were diluted 1:500 and tested for anti-dsDNA reactivity by ELISA as
described below. The amount of antibodies per kidney is given as U/μg tissue and was
calculated as: [Ab, U/μl] / [μg kidney/μl elution volume].

2.2.4 In vitro B cell differentiation
Flow-sorted CD19high B cells (2 x 105/well) were plated with variable numbers of flow
sorted Gr1highCD11b+ or Gr1lowCD11b+ cells in the presence or absence of
recombinant IFNα (500 units/ml, PBL InterferonSource) and recombinant CD40L
(10μg/ml, EBiosciences) in complete media (RPMI1640 w/ 10% FBS, 1% non-essential
amino acids, 1% pen/strep, 1mM Na-Pyruvate). After 72 hrs, cells were harvested and
25.000 cells/well were transferred onto ELISPOT plates (Millipore) pre-coated with antiIg antibody (Southern Biotech). Remaining cells were stained for Gr1 and B220expressing cells and analyzed for the relative survival of each cell subset by flow
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cytometry. After additional 20hrs, cells were removed and plates were developed using
HRP-conjugated anti-IgG and anti-IgM specific secondary antibodies (KPL and Southern
Biotech) and AEC Substrate set (BD Biosciences). The numbers of IgM or IgG-secreting
cells were detected on an ELISPOT reader (CTL Immunospot) and are given as number
of spots per 105 B cells. Where noted, sorted Gr1highCD11b+ cells were pretreated with
20mM N-Acetyl-L-Cysteine (NAC) a ROS inhibitor (Sigma, MO) or 10μM Nω-LArginine methyl ester hydrochloride (L-NAME) a NOS inhibitor (Sigma, MO) for 30
min. at 37°C, before being added to CD19+ B cells.

2.2.5 Anti-nuclear Autoantibody ELISA
Serum obtained from anti-Gr1 antibody and control-treated animals, before, during and
after treatment ended, was diluted 1:300 in serum diluent (sterile filtered 0.5% bovine γglobulin, 5% gelatin, 0.05mM Tween in 1x PBS) and analyzed for levels of antichromatin, anti-histone and anti-dsDNA IgG autoantibodies. Briefly, microtiter plates
(Immulon 2HD) were coated with purified chromatin or total histones over night at 4°C,
blocked in 5% gelatin/PBS for ≥2hrs, and incubated with samples for 2 hrs. Secondary
HRP-conjugated anti-mouse IgG antibodies (Invitrogen) were added for 1.5 hrs and
plates were developed using 10mg/ml 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid)(ABTS) in McllWain’s buffer (0.09 M Na2HPO4, 0.06 M citric acid, pH 4.6). AntidsDNA IgG IgG levels were determined using the manufacturer’s protocol (Alpha
Diagnostic International Inc., TX).
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2.2.6 Cytokine ELISA
Serum cytokine levels were measured using the manufacturer’s protocols (BAFF and IL10 (EBiosciences), IL-6 (R&D Systems)). Briefly, serum samples were diluted 1:3
(BAFF), 1:10 (IL-6), or 1:4 (IL-10) and added to pre-coated Immulon 2-HB microtitre
plates (Thermo Scientific, MA). Concentrations of serum cytokines were calculated
based on OD values obtained from the supplied recombinant cytokine standard. All
calculations were done using GraphPad Prism software (ver. 5.02).

2.2.7 Statistical analyses
The statistical significance between the means of two groups was determined using
Student’s t-test or the non-parametric Mann-Whitney test.
2.3. Results

2.3.1. NZB x NZW)F1 male mice harbor elevated levels of Gr1highCD11b+ cells as
compared with age-matched (NZB x NZW)F1 female mice
To identify potential immune mechanisms acting differentially in males and females prior
to puberty, we analyzed the cellular immune compartment present in spleens of male and
female lupus-prone (NZB X NZW)F1 mice at 4 weeks of age. Contrary to our
expectations, we found no significant differences between the sexes within
subpopulations of T cells, B cells, and dendritic cells (Figure 2.1 A). Rather, we found
consistently elevated levels of two myeloid cell populations characterized by the coexpression of CD11b (Mac-1) and Gr1 (Ly6G/Ly6C): Gr1highCD11b+ and Gr1lowCD11b+
cells (Figure 2.1 A-B, p < 0.01). Further analyses showed that splenic Gr1highCD11b+
cells were significantly elevated in males as compared with females in percentages (p <
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0.05-0.001), as well as in total numbers (p < 0.05-0.01), throughout the first 6 months of
life (Figure 2.1 C, left panel). Total numbers of the corresponding population of splenic
Gr1lowCD11b+ cells were also significantly elevated in 4 wk old male (NZB x NZW)F1
mice as compared with females (p < 0.01), but not in older mice (Figure 2.1 C, right
panel). To determine if the elevated levels of Gr1highCD11b+ cells in male mice were due
to regulation by male sex hormone, we analyzed levels of cells in castrated and hormonereconstituted (NZB x NZW)F1 mice. Both numbers and percentages of splenic
Gr1highCD11b+ cells significantly decreased in castrated male, but not ovariectomized
female, mice as compared with unmanipulated littermates (p < 0.001; Figure 2.1 D). The
effect was specific to the effect of testosterone, as reconstitution of castrated male mice
with 5α-dihydrotestosterone, which cannot be converted to estradiol, replenished levels
of Gr1highCD11b+ cells. (p < 0.0001; Figure 2.1 D).
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Figure 2.1 Elevated levels of splenic Gr1highCD11b+ cells in male as compared with
female (NZB x NZW)F1 mice. (A) Percentages of T cells, B cells, DCs and monocytes
in 4 wk old male (M) and female (F) (NZB x NZW)F1 mice. Each data point represents
an individual mouse. Tr: Transitional B cells, FM: Follicular Mature B cells, MZ:
Marginal Zone B cells, PC: Plasma Cells, cDCs: conventional DCs (CD11c+B220-),
pDCs: plasmacytoid dendritic cells (CD11c+B220+). (B) Representative contour plots
showing the levels of Gr1highCD11b+ and Gr1lowCD11b+ cells in 4 wk old male and
female (NZB x NZW)F1 mice. (C) Absolute numbers and percentages of Gr1highCD11b+
cells (left panel) and Gr1lowCD11b+ cells (right panel) in male (black diamonds, black
bars) and female (gray triangles, gray bars) in 4, 9 and 26 week old (NZB x NZW)F1
mice. Data are shown as the average ± SEM of cells in ≥5 individual mice obtained in >5
independent analyses. (D) Splenic Gr1highCD11b+ cells are regulated by testosterone.
Percentage of cells was measured 5 weeks post-surgery in unmanipulated (black
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diamonds), castrated (white diamonds) and castrated + 5α-dihydro-testosterone treated
(gray diamonds) mice. * p < 0.05; ** p < 0.01; *** p < 0.001.

2.3.2. Gr1+CD11b+ cells in young (NZB x NZW)F1 mice locate to the perifollicular
regions of the spleen and share surface markers with both neutrophils and MDSCs
Gr1-expressing cells have recently been found to locate to the perifollicular region in
healthy humans and non-autoimmune mice (113). Confocal imaging of immunostained 4
wk old (NZB x NZW)F1 mouse spleen sections confirmed the localization of
Gr1+CD11b+ cells adjacent to B lymphocytes (Figure 2.2 A). The pattern of localization
was not significantly different between males and females, although we observed slightly
more Gr1+ cells within the marginal zone areas of males than of females (Figure 2.2 A ac, arrows). We further characterized the cells with regard to cellular morphology and cell
surface

marker

expression:

Gr1highCD11b+

cells

had

a

phenotype

of

Ly6G+Ly6ClowCD49d-F4/80-CD124- and displayed a neutrophilic nuclear morphology,
while Gr1lowCD11b+ cells were Ly6G-Ly6ChighCD49d+F4/80+CD124low and had a
monocytic appearance (Figure 2.2 B-C). These patterns are shared with, but not exclusive
to, monocytic and neutrophilic MDSCs (121,175,180,181). In addition, we found that 1525% of splenic Gr1highCD11b+ cells from 4 wk old (NZB x NZW)F1 male and female
mice coexpressed CXCR2, the prototypic surface chemokine receptor of mature
neutrophils (Figure 2.2 C, bottom panel). CXCR2 was not expressed by Gr1lowCD11b+
cells.
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Figure 2.2 Gr1highCD11b+ cells display phenotypic characteristics of granulocytic
myeloid-derived suppressor cells. (A) Confocal microscopy analysis of the intra-splenic
localization of Gr1-expressing cells in 4 week old female (a,b) or male (c) (NZB x
NZW)F1 mice. Stippled lines (a and c) outlines B cell follicle and arrows (a and c) point
to Gr1-expressing cells within the peri-follicular region. B: B cell follicle; T: T cell zone.
Pictures were taken at 40x magnification and are representative of 5 female and 4 male
28 samples. (B) Cytospin analysis of Gr1lowCD11b+ and Gr1highCD11b+ cells. Nuclear
morphology was determined after H&E staining. (C) Flow cytometry analysis of cell
surface markers on Gr1lowCD11b+ and Gr1highCD11b+ cells from 4 wk old (NZB x
NZW)F1 mice. Cells were costained for Ly6C, Ly6G, CD49d, F4/80, CD124 (IL-4rα)
and CXCR2. Level of expression of each marker is given in a histogram (blue line: male;
red line: female) after gating on each subset individually. Data represent 3 or more
independent analyses.
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2.3.3. Gr1-expressing cells suppress autoantibody production, IL-10 production, and
lupus-like disease in male, but not female (NZB x NZW)F1 mice in vivo.
Given the well-known differential development of lupus-like disease in (NZB x NZW)F1
males and females, we investigated if the uneven levels of Gr1highCD11b+ and
Gr1lowCD11b+ cells in male and female mice could be involved in the control of
spontaneous lupus-like disease. We treated adult 11-15 wk old male and female (NZB x
NZW)F1 mice with depleting anti-Gr1 antibody every three days for 8 weeks
determining disease activity by means of serum anti-nuclear autoantibody levels and
proteinuria. Functional depletion was verified in PBMC fractions after 4 and 6 weeks of
depletion; levels of circulating Gr1+CD11b+ cells were constitutively reduced among
total PBMCs from both males (from 28% to 9.2%) and females (from 15% to 9.5%).
Continuous anti-Gr1 antibody treatment of male (NZB x NZW)F1 mice resulted in
significantly elevated levels of serum anti-dsDNA IgG during and after ended treatment
(p < 0.05)(Figure 2.3 A, right panel), as well as transiently elevated anti-histone IgG
levels (Figure 3A, left panel) and IgG antichromatin (data not shown). In contrast, antiGr1 antibody treatment of female (NZB x NZW)F1 mice had little or no effect on the
level of anti-nuclear IgG autoantibodies (Figure 2.3 B).
Other serological abnormalities previously identified in female (NZB x NZW)F1 mice
include elevated BAFF, IL-6 and IL-10 (109,182-184). Quantification of these factors in
anti-Gr1 antibody treated mice, showed significantly elevated levels of serum IL-10 in
response to the depletion of Gr1+ cells in both male and female mice (Figure 2.3 C-D),
but no differences in serum levels of either BAFF or IL-6 (data not shown).
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Figure 2.3 In vivo depletion of Gr1-expressing cells increases autoantibody
production and IL-10 secretion in male (NZB x NZW)F1 mice. Male (A) or female
(B) (NZB x NZW)F1 mice were treated with 500μg anti-Gr1 antibody (black squares),
rat IgG antibody (gray triangles) or PBS (white triangles) every 3 days for 8 weeks (gray
shaded area) starting at 11-15 weeks of age. Serum samples were obtained before, during
and after treatment and levels of anti-histone IgG (left side panels) and anti-dsDNA IgG
(right side panels) were determined by ELISA. The p-value for anti-Gr1 treated versus rat
IgG-treated mice is given in the upper right corner of each graph. Statistical comparison
of autoantibody levels at individual time points is given by asterisks (*). (C-D) Serum IL10 levels were measured in male (C) and female (D) (NZB x NZW)F1 after ended
treatment at 19-23 weeks of age. n = 8 (anti-Gr1 IgG treated males, females), n = 7 and 3
(rat IgG treated males, females, respectively), n = 4 and 2 (PBS-treated males, females,
respectively). * p< 0.05; ** p < 0.01; *** p < 0.001.
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2.3.4. The development of glomerulonephritis is unaffected by anti-Gr1 Ab
treatment
Lupus-like disease in (NZB x NZW)F1 mice is also characterized by glomerulonephritis,
glomerular IgG-IC deposition, and complement fixation. Anti-Gr1 antibody treated male
(NZB x NZW)F1 mice displayed no significant differences in glomerular size and
cellularity, or tubulointerstitial inflammation (Figure 2.4 A-B).

Figure 2.4 The development of glomerulonephritis is unaffected by anti-Gr1 Ab
treatment. (A) Representative pictures of hematoxylin/eosin stained kidney sections
from male (NZB x NZW)F1 mice treated with PBS (upper left), rat IgG control Ab
(upper right), or rat anti-Gr1 Ab (lower left) 8 weeks post treatment. Arrows point to
glomeruli. (B) The area per glomerulus was calculated for PBS-treated (n = 4 mice), rat
IgG-treated (n = 5 mice), and anti-Gr1 Ab-treated (n = 6 mice). Each dot represents the
average of 3-5 glomeruli per mouse.
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2.3.5. IgG-IC deposition is increased in anti-Gr1 treated male mice
IgG-IC deposition was significantly elevated within the kidney glomeruli of anti-Gr1
antibody treated males, reaching levels equivalent to female age-matched control mice
(Figure 2.5 A-B). This pattern was specific to IgG-IC, as no increase was observed in the
levels of IgM deposition (Figure 2.5 B). Further analysis of the specificity of deposited
autoantibodies after elution from a subset of the kidneys revealed elevated levels of antidsDNA IgG autoantibodies in anti-Gr1 antibody treated males (Figure 2.5 C).
Complement fixation, as measured by C3 immunostaining, was not increased in the antiGr1 antibody treated group (Figure 2.5 B) and renal failure was not observed in any of
the mice (dipstick proteinuria readings: PBS treated = 1.5 ± 0.0 (n = 4); rat IgG Abtreated = 1.3 ± 0.7 (n = 5); anti-Gr1 Ab treated = 1.6 ± 0.3 (n = 7)). Thus, depletion of
Gr1-expressing cells at 11-15 wks of age resulted in elevated levels of serum antidsDNA, anti-histone and anti-chromatin IgG, elevated serum IL-10, as well as increased
anti-dsDNA IgG deposition in male mice. In female mice, depletion of Gr1-expressing
cells resulted in equally elevated levels of serum IL-10, but no increase in anti-nuclear
autoantibody production.
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Figure 2.5 IgG-IC deposition is increased in anti-Gr1 treated male mice. (A)
Representative immunofluorescence staining of IgG (red) and C3 (green) deposition in
anti-Gr1 Ab, rat IgG, or PBS treated males, as well as age-matched untreated control
females. Pictures shown are representative of 4-6 mice per group. (B) Quantification of
the level of IgG, IgM and C3 staining per glomerulus as shown in (A). Quantification
data represent the average level of staining in individual mice ± standard error of the
mean (4-6 mice per group and 5-12 glomeruli per mouse were analyzed). (C) Levels of
dsDNA reactive IgG’s were measured by ELISA after elution of total antibodies from a
subset of frozen kidneys.* p < 0.05.
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2.3.6. Gr-1highCD11b+ cells directly suppress B cell differentiation in vitro
Based on the intra-splenic localization of Gr1-expressing cells and the effect on antinuclear autoantibody production after Gr1+-cell depletion in male (NZB x NZW)F1 mice,
we hypothesized that Gr1highCD11b+ cells were involved in the control of B cell
activation, differentiation and/or effector mechanisms. We therefore tested if
Gr1highCD11b+ or Gr1lowCD11b+ cells isolated from male and female 4 wk old (NZB x
NZW)F1 mice could directly suppress B cell differentiation in vitro in a T cell-free
system. Upon coculture with increasing numbers of Gr1highCD11b+ cells, but not
Gr1lowCD11b+ cells, cytokine-driven B cell differentiation was significantly inhibited in a
dose dependent manner (Figure 2.6 A-B). The suppressive effect was equally present
using Gr1highCD11b+ cells from 4 wk old male or female mice.
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Figure 2.6 Gr1highCD11b+ cells, but not Gr1lowCD11b+ cells, suppress B cell
differentiation in vitro. B cells (CD19high), Gr1lowCD11b+ and Gr1highCD11b+ cells were
isolated from spleens of 4 wk old male (A) or female (B) mice and co-cultured for 72 hrs
at variable ratios (B cell to Gr1-cell ratios: 4:1, 8:1 or 16:1) in the presence of B cell
differentiation-inducing cytokines (recombinant IFNα and CD40L). Total numbers of
IgM- and/or IgG-secreting plasma cells were detected by ELISPOT and are given as the
number of spots per 105 B cells. Each bar represents the mean ± SEM. Data represent 5-8
independent assays. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.
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2.3.7. Gr-1highCD11b+ cells from female, but not male, (NZB x NZW)F1 mice
suppress B cell differentiation via ROS/nitric oxide (NO)
Gr1-expressing cells have been reported to suppress adaptive immune responses via
numerous suppressor mechanisms including the production of reactive oxygen species
(ROS) and nitric oxide (NO)(reviewed in (175)). Pretreatment of Gr1highCD11b+ cells
from female (NZB x NZW)F1 mice with inhibitors of either ROS or NO synthase (NOS)
completely abrogated the suppressive effect of the cells (Figure 2.7 , right-side panel). In
contrast, similar treatment of male-derived Gr1highCD11b+ cells had no effect on the
suppressive capacity of the cells (Figure 2.7, left-side panel). Thus, although male and
female Gr1highCD11b+ cells from 4 week old prepubertal (NZB x NZW)F1 mice suppress
B cell differentiation equally well, the cells appear to operate through different molecular
mechanisms.
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Figure 2.7 Gr-1highCD11b+ cells from female, but not male, (NZB x NZW)F1 mice
suppress B cell differentiation via ROS/nitric oxide (NO). Gr1highCD11b+ cells were
isolated from spleens of 4 wk old male or female mice and were pretreated with LNAME (NOS inhibitor) or NAC (ROS inhibitor) before added to B cells and co-cultured
with B cells as described earlier. Gr1highCD11b+ cells each bar represents the mean ±
SEM. Data represent 5-8 independent assays. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.
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2.3.8 Male Gr1highCD11b+ cells remain suppressive in older mice
The in vivo effect of Gr1+-cell depletion, as described above, was measured in older mice.
We therefore analyzed the effect of Gr1highCD11b+ and Gr1lowCD11b+ cells isolated from
14-16 wk old mice. Interestingly, male Gr1highCD11b+ cells from 14-16 wk old mice
remained suppressive at the 4:1 ratio [B cells : Gr1highCD11b+ cells] (p < 0.01), while
female Gr1highCD11b+ cells lost their suppressive capacity (p = 0.27) (Figure 2.8 A-B).
This was not due to a defect in the B cells from older (NZB x NZW)F1 females, as these
cells could be suppressed using Gr1highCD11b+ cells isolated from either 4 wk old
females or 14 wk old males (Figure 2.8 B).

Figure 2.8 Only male Gr1highCD11b+ cells remain suppressive in older mice.
Gr1highCD11b+ cells were flow sorted cells from 14-16 wk old male (A) and female (B)
(NZB x NZW)F1 mice and added to B cell cultures in the presence of CD40L and IFNα
(n = 7-8). Numbers of IgM or IgG producing plasma cells were enumerated by ELISPOT
after 4 days. In (B) B cells isolated from 14 wk old female (NZB x NZW)F1 mice were
exposed to Gr1highCD11b+ cells from either 14 wk old females at 4:1, 8:1 or 16:1 ratios (n
= 7), or from 4 wk old female or 14 wk old male (NZB x NZW)F1 mice at a 4:1 ratio
(each n = 2). * p < 0.05; ** p < 0.01; *** p < 0.001. ns: not statistically significant.
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2.3.9 Gr1lowCD11b+ cells from older male and female (NZB x NZW)F1 mice
stimulate B cell differentiation in vitro.
As female (NZB x NZW)F1 mice age, the ratio of Gr1highCD11b+ to Gr1lowCD11b+ cells
change in favor of the monocytic Gr1lowCD11b+ population (see Figure 2.1). At the same
time, anti-Gr1 antibody treatment failed to affect anti-nuclear autoantibody production in
females in vivo (see Figure 2.3). We speculated that Gr1lowCD11b+ cells in adult (NZB x
NZW)F1 mice acquired a stimulatory phenotype, as previously described in both SLE
patients and a pristane-induced model of lupus (113,185,186). In agreement,
Gr1lowCD11b+ cells from both male and female 14-16 wk old (NZB x NZW)F1 mice
exhibited a stimulatory phenotype promoting B cell differentiation in our T-cell free in
vitro cell system (p < 0.05) (Fig. 9 A-B).

A

B

Figure 2.9 Gr1lowCD11b+ cells from older male and female (NZB x NZW)F1 mice
stimulate B cell differentiation in vitro. In older mice, Gr1lowCD11b+ cells become
immunostimulatory. Gr1lowCD11b+ cells were flow sorted cells from 14-16 wk old male
(A) and female (B) (NZB x NZW)F1 mice and added to B cell cultures in the presence of
CD40L and IFNα (n = 7-8). Numbers of IgM or IgG producing plasma cells were
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enumerated by ELISPOT after 4 days. * p < 0.05; ** p < 0.01; *** p < 0.001. ns: not
statistically significant.
2.4 Discussion
SLE predominantly affects females. Over the past many years, it has been known that the
male sex hormone, testosterone, exerts suppressive functions on disease development and
severity (70,72,73,167-170). However, the mechanism(s) by which testosterone may
influence the immune system of lupus-prone individuals in a protective manner is not
well understood. In this study we investigated a mechanism of immunosuppression
mediated by a population of myeloid cells (Gr1highLy6G+CD11b+), found to be present at
higher levels in male than female lupus-prone (NZB x NZW)F1 mice. Manipulation of
testosterone levels through pre-pubertal castration, but not estrogen levels, significantly
influenced the levels of Gr1highCD11b+ cells in vivo, suggesting that this
immunosuppressive mechanism is regulated by male sex hormone. We propose that
regulation of immunosuppressive Gr1highCD11b+ cells represent one of the missing links
in testosterone-mediated protection from SLE and lupus-like disease.
It is likely that Gr1highCD11b+ cells are a heterogeneous population consisting of one or
more of several identified cell subsets, such as neutrophils, dendritic cell precursors and
immature monocytes (175). All of these cell subsets are well-documented
immunostimulatory players in the pathogenesis of established lupus as compared with
healthy individuals without an autoimmune disease (101,187,188), but to our knowledge,
no study has analyzed the numbers and function of the cells in genetically predisposed
but undiagnosed male versus female individuals. Our data shows that Gr1-expressing
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cells are immunosuppressive in young lupus-prone male and female mice, but that the
cells remain immunosuppressive in older male mice only. Consistent with this finding,
depletion of Gr-1highCD11b+ cells in male (NZB x NZW)F1 mice resulted in increased
serum ANA levels, while depletion in female mice had no significant effect. Despite
increased deposition of IgG anti-dsDNA antibodies in the kidneys of male (NZB x
NZW)F1 mice, they did not develop renal damage or proteinuria. The dissociation of
antibody levels, IgG IC deposition, and renal disease is a well-known phenomenon that
has been observed in many mouse models of SLE (189-191), suggesting that either 1)
antibodies with alternate, as-yet-unknown specificities are involved in the pathogenesis
of the disease or 2) additional, potentially female-intrinsic factors are required to confer
susceptibility to end-organ—in this case, kidney— damage.

Gr1-expressing cells can suppress immune functions by numerous different mechanisms
including ROS, NO, IL-10, TGFβ and arginase-1 (175). We do not believe IL-10 and
TGFβ are involved in directly suppressing B cell differentiation, as targeting IL-10 or
TGFβ by neutralizing antibodies in our in vitro B cell stimulation assay failed to reverse
the suppressor capacity of male and female Gr1highCD11b+ cells from male and female
mice (Khan and Jorgensen, unpublished observation). In fact, removal of Gr1-expressing
cells in vivo resulted in significantly elevated levels of IL-10, confirming a potential
disease-promoting effect of this cytokine, as previously suggested in both human and
animal studies (137,183). Ongoing studies aim at identifying the cellular source of this
IL-10 and determining whether IL-10 is indeed involved in driving autoantibody
production in anti-Gr1 antibody-depleted male (NZB x NZW)F1 mice.

60

In vitro, we found ROS/NO production to be critical for suppression of B cell
differentiation by Gr1highCD11b+ from female (NZB x NZW)F1 mice. ROS and NO are
most often associated with pro-inflammatory conditions, and levels of ROS are in fact
elevated in SLE patients, especially within neutrophils, and correlated with SLEDAI
scores (192,193). Similarly, elevated ROS levels have been documented in BALB/c mice
with pristane-induced lupus and in the MRLlpr/lpr mouse model of lupus (194,195).
Furthermore, inhibition of inducible NOS in female (NZB x NZW)F1 mice with
proteinuria suppresses renal disease via reductions in ROS levels (196). It remains to be
seen whether excessive ROS/NO production by Gr-1–expressing cells from young female
mice is involved in the disease progression in older mice. As shown in our in vitro B cell
differentiation assay, Gr-1highCD11b+ cells from 4-week-old male (NZB x NZW)F1 mice
did not use ROS/NO as their mechanism of suppression. It is therefore possible that the
heterogeneous population of Gr-1highCD11b+ cells is composed of different cell subsets in
male mice as compared with female mice. Identification of the specific subset of Gr1highCD11b+ cells with ROS/NO independent suppressor capacities in male (NZB x
NZW)F1 mice will be of utmost interest in our search for new diagnostic tools and
treatment strategies. These data obtained in mice lead us to suggest those differential
levels of Gr-1highCD11b+ cells, as well as the potential usage of different suppressor
mechanisms—if ultimately detected in humans as well—might be actively involved in
delaying or preventing SLE in otherwise genetically predisposed male mice.

In addition to the Gr1highCD11b+ cells, a population of Gr1lowLy6G-CD11b+ cells is also
present at higher levels in males before puberty (at 4 weeks of age), but increases in
61

females as they age. This population of cells concurrently acquires a stimulatory
phenotype promoting cytokine-dependent B cell differentiation in vitro. A positive
correlation between the numbers of Gr1lowCD11b+ cells and autoantibody production has
also previously been observed in a model of pristine-induced lupus (186), and a similar
population of cells was recently found to promote T-cell independent B cell
differentiation in humans (113). Whether the age-dependent accumulation of
Gr1lowCD11b+ cells in female (NZB x NZW)F1 mice is a result of disease progression
and underlying inflammation remains to be determined.
Based on our findings reported here, we suggest that the balance between Gr1highCD11b+
and Gr1lowCD11b+ cells, as well as the composition of cells within the Gr1highCD11b+
cell population, may be instrumental in protecting genetically predisposed males from
lupus-like disease development. Both male and female (NZB x NZW)F1 mice display 23 times more Gr1highCD11b+ cells than Gr1lowCD11b+ cells before puberty, and hence
maintain an immunoinhibitory milieu. The ratio remains in favor of Gr1highCD11b+ cells
in males up until at least 26 wks of age, however already around 9 weeks of age, female
(NZB x NZW)F1 mice harbored higher numbers of Gr1 lowCD11b+ cells than
Gr1highCD11b+ cells. Thus, as the females enter puberty the balance shifts towards the
more immunostimulatory population. We therefore suggest that testosterone mediates its
suppressive effect via the maintenance of a population of immunoinhibitory
Gr1highCD11b+ cells. Our studies further suggest that this population is specifically
involved in limiting the production of pathogenic IL-10 in vivo. Studies addressing ways
to induce higher numbers of suppressive, ROS/NO-independent, Gr1highCD11b+ cells in
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females is therefore of outmost interest as we aim to identify ways to delay or prevent B
cell activation, differentiation and ultimately lupus-like disease.

Finally, it is worth mentioning, that although the majority of male mice harbor elevated
numbers of Gr1highLy6G+CD11b+ cells as compared with female mice, a subset of mice
(~25%) demonstrated less of an increase. This proportion correlates with the number of
male (NZB x NZW)F1 mice that will develop a lupus-like disease within the first year of
life (30-40%). Thus, measurements of prepubertal levels of Gr1highCD11b+ cells could
potentially be used as a diagnostic tool, while manipulation of Gr1-expressing cell
populations may represent a new target for immune intervention.
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CHAPTER III

GR1+ CELLS SUPPRESS T DEPENDENT ANTIBODY RESPONSES IN (NZB x
NZW)F1 MALE MICE THROUGH INHIBITION OF T FOLLICULAR HELPER
CELLS AND GERMINAL CENTER FORMATION

Abstract
Systemic lupus erythematosus is an autoimmune disease characterized by elevated
production of autoreactive Abs. The disease has a much higher prevalence in women than
in men. Although testosterone has been shown to be protective in the disease, and
estrogens exacerbating, the discrepancy in prevalence between men and women is still
not well understood and the mechanism behind it is unknown. We have recently
described that male (New Zealand black [NZB] x New Zealand white [NZW])F1 mice
have higher levels of Gr1+CD11b+ cells, and that these cells suppress autoantibody
production in vivo. In this article, we extend our findings to show that similarly to
humans, female lupus-prone (NZB x NZW)F1 mice also respond with stronger Ab
responses to thymus dependent Ag immunization than male littermates. Furthermore, the
presence or absence of Gr1-expressing cells not only control Ag-specific Ab responses in
male, but not female, (NZB x NZW)F1 mice, but also significantly alter the activation
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and differentiation of CD4+ T cells in vitro and in vivo. In particular, we found that Gr1+
cells from male (NZB x NZW)F1 mice suppress the differentiation and effector function
of CXCR5+PD-1+ T follicular helper cells, thereby controlling germinal center formation
and plasma cell differentiation. This new finding strongly supports efforts to develop new
drugs that target myeloid cell subsets in a number of T and B cell–mediated diseases with
a female predominance.

3.1 Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the
production of autoreactive Abs resulting in a variety of symptoms including fatigue, skin
rashes, arthritis, and nephropathy leading to renal failure (1,197,198). One mouse model
used to study lupus is the (New Zealand black [NZB] x New Zealand white [NZW]) F1
strain. Lupus-like disease in the (NZB x NZW)F1 mice is characterized by hyperactive B
cells, abnormal autoantibody production, and ectopic germinal center (GC) formation,
and has been shown to depend on CD4+T cell help (127,128,199,200). Upon activation,
CD4+ T cells can differentiate into several effector cell subsets characterized by their
unique production of effector cytokines, that is, Th1 (IFN-γ), Th2 (IL-4, IL-5), Th9 (IL9), Th17 (IL-17), or T follicular helper cells (TFH; IL-21). Although all of these subsets
can influence B cell activation and/or differentiation, IL-21–producing TFH cells are
critically required for GC formation and plasma cell (PC) differentiation (154,201,202).
Consistent with lupus being a B cell–dependent, autoantibody mediated disease; TFH cells
and IL-21 have been found to be involved in at least some aspects of lupus-like disease
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development in several mouse models (203-205). Importantly, studies have also
demonstrated dysregulated TFH cells in SLE patients (153,206,207).

Like many other autoimmune diseases, SLE disproportionately affects women more than
men (64). Hormonal therapy has been successfully applied in severe cases of SLE,
suggesting that sex hormones play a major role in determining disease development in
genetically predisposed individuals (168-170). Likewise, female (NZB x NZW)F1 mice
develop lupus-like disease with a much higher incidence than male (NZB x NZW)F1
mice (70,71). The female predominance observed in the (NZB x NZW)F1 mouse model
is known to be controlled in part by sex hormones (72,73,81,208,209). Interestingly, it
has been suggested that sex hormones also partake in defining the magnitude of immune
activation during infections and after immunizations in healthy individuals ((209) and
reviewed in Ref. (210)).

Our laboratory recently described the presence of a population of testosterone-regulated
immunosuppressive Gr1+CD11b+ cells in male (NZB x NZW)F1 mice (211).
Particularly, we found that depletion of Gr1-expressing cells augmented spontaneous
autoantibody production in male (NZB x NZW)F1 mice, whereas a similar strategy had
no effect on autoantibody production in female mice. In this study, we tested whether the
immune-suppressive function of Gr1+CD11b+ cells observed in male lupus-prone (NZB x
NZW)F1 mice also affected immune activation in response to exogenous Ag. As
expected, male (NZB x NZW)F1 mice responded less vigorously to immunization with a
T-dependent Ag, whereas depletion of Gr1-expressing cells augmented the Ag-dependent
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Ab response in males, but not in females. In correlation, numbers of both T FH cells and
GC B cells were elevated after Gr1+ cell depletion. Thus, manipulation of analogous
human cells might offer a new potential target for improving vaccination efficacy in
individuals with low Ab responses, as well as repressing Ab production in systemic
autoimmunity.

3.2 Materials and Methods

3.2.1 Mice and Immunizations
Three-week-old male and female (NZB x NZW)F1 mice were obtained from The Jackson
Laboratories and kept at the Biological Resource Unit at Lerner Research Institute,
Cleveland Clinic. All mouse experiments were approved by the local Institutional Animal
Care and Use Committee. Mice were bled at 8 wk of age, and PBMCs were analyzed for
the presence of Gr1+CD11b+ cells by flow cytometry, allowing for stratification of the
mice into equal groups based on their basal levels of Gr1+CD11b+ cells. At 9 wk of age,
mice were injected i.p. with 20 μg (4-hydroxy-3-nitrophenylacetyl)27 conjugated chicken
γ-globulin (NP27-CGG) or NP27-FICOLL [both from Biosearch Technologies, Petaluma,
CA]), in a ratio of 1:1 with CFA (Sigma-Aldrich, St. Louis, MO), or with 1x PBS. Each
injection was done in a total volume of 200 μl. Ab-treated mice were additionally injected
i.p. every 3 d starting on day 21 with either 500 μg rat anti-mouse Gr1 (clone RB6-8C5, a
kind gift from Dr. Pearlman, Case Western Reserve University, Cleveland, OH), 500 μg
control rat IgG, or sterile-filtered PBS, each in a total volume of 200 μl as previously
described (211). This treatment strategy was based on data showing that Gr1-expressing
cells were fully depleted from BM, spleen, and blood for 2 d, and only began to reappear
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on day 3 after injection with anti-Gr1 Ab (data not shown). Ab treatment was continued
for up to 28 d as stated in the text. Mice were bled for serum by tail-vein bleeding on day
-1, day 7, and every 7 d thereafter as applicable.

3.2.2 Flow cytometry
Flow cytometry was performed using a FACSCalibur (BD Biosciences, San Jose, CA),
and all analyses were done using FlowJo Version 9.3. Abs with the following
specificities were used for all analyses: FITC-conjugated anti- CD3 (clone 145-2C11),
PE- or allophycocyanin-conjugated anti-CD4 (clone L3T4), PerCP-conjugated anti-CD8
(clone 53-6.7), PE- or allophycocyanin-conjugated anti-CD11b (clone M1/70), PEconjugated anti-CD38 (clone 90), FITC- or PerCP-conjugated anti-B220 (CD45R; clone
RA3-6B2), FITC-conjugated anti-CD62L (clone MEL-14), PerCP-conjugated anti-Gr1
(Ly6G/6C; clone RB6-8C5), biotin-conjugated anti–GL-7 (clone GL-7), PE-conjugated
anti-CD278 (ICOS; clone 7E.17G9), PE-conjugated anti-CD279 (PD-1; clone MIH4),
and PE-conjugated streptavidin (all from eBioscience, San Diego, CA). PE-conjugated
anti-CD138 (clone 281-2) and biotin-conjugated anti-CXCR5 (clone 2G8) Abs were
purchased from BD Biosciences. All flow-based analyses were based on the gating of
live cells as given by forward and side scatter properties.

3.2.3 ELISA
Serum was obtained from NP27-CGG immunized anti-Gr1 Ab and control Ab-treated
animals before, during, and after treatment. 2HB (Immulon) 96-well microtiter plates
were coated with 5 μg/well NP5 conjugated to BSA in PBS overnight and blocked for 2 h
at room temperature with 5% gelatin in PBS. Serum was diluted 1:10,000 in serum
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diluent (5 μg/ml bovine γ-globulin, 5% gelatin, 0.05% Tween in PBS). A total of 100 μl/
well diluted serum was plated and incubated for 2 h at room temperature. All washes
were done using 0.05% Tween in PBS. Plates were developed using HRP-conjugated
anti-IgG1 secondary Abs and 10 μg/ml 2,29-azinobis(3-ethylbenzthiazoline-6-sulphonic
acid) in Mcilwain’s buffer (0.09 M Na2HPO4, 0.06 M citric acid, pH 4.6), and
colorimetric readings were done at 405 nm on a Victor 3 plate reader (Perkin Elmer,
Waltham, MA). All samples per experiment were run at the same time, allowing for
direct comparisons of OD values to determine Ab levels between samples.

3.2.4 T cell proliferation assay
Spleen single cells were prepared from 9-wk-old male and female (NZB xNZW)F1 mice.
Gr1highCD11b+ and Gr1lowCD11b+ cells were sorted by high-speed cell sorting
(FACSAria II; BD Biosciences). Total T cells were isolated from female (NZB x
NZW)F1 age-matched mice by MACS separation using CD90.2 microbeads (Miltenyi
Biotech, CA). After isolation, T cells were labeled with CFSE (Sigma-Aldrich). After
labeling, cells were washed and reconstituted in cell culture media (RPMI 1640, 10%
FBS, 1% Penicillin/Streptomycin, 1 μM Na-pyruvate, 1xMEM). A total of 2 x 105 T
cells/well were plated in 96-well microtiter plates in the presence or absence of platebound anti-CD3 and anti-CD28 Abs (10 μg/ml each; both from eBioscience). Where
noted, 5 x104 flow-sorted Gr1highCD11b+ or GR1low CD11b+ cells were added to the
cultures at time 0 h. After 48 hr, cells were harvested and stained with allophycocyaninconjugated anti- CD4 and PerCP-conjugated anti-CD8 Abs (eBioscience), allowing for
separate analysis of proliferation of CD4+ and CD8+ T cell subsets.
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3.2.5 TFH cell differentiation assay
Naive CD90.2+CD62Lhigh T cells and Gr1+CD11b+ cells were sorted by high-speed cell
sorting (FACSAriaII; BD Biosciences) from spleens of 9-wk-old male (NZB x NZW)F1
mice. A total of 3 x 105 naive T cells was plated in the presence or absence of
Gr1+CD11b+ cells at different ratios (Gr1+/T cell ratio = 1:4, 1:8, and 1:16). Cells were
cultured in cell culture media (RPMI 1640, 10% FBS, 1% Penicillin/Streptomycin, 1 μM
Napyruvate, 1x MEM) in the presence of plate-bound anti-CD3 and anti- CD28 Abs (3
μg/ml each), 10 μg/ml anti–IL-4 Ab (eBioscience), 10 μg/ml anti–IFN-γ Ab
(eBioscience), 20 μg/ml anti–TGF-b Ab (R&D Systems, Minneapolis, MN), 50 ng/ml
rIL-21, and 100 ng/ml IL-6 (both from Biolegend, San Diego, CA) (29). The media were
replaced with fresh media containing the same amounts of cytokines on day 3. After 5 d,
cells were harvested and stained using the following Abs and conjugates: anti–PD-1
(FITC), biotinylated anti-CXCR5 and streptavidin-PE conjugate, anti-Gr1 (PerCP), and
anti-CD4 (allophycocyanin; all from eBioscience). TFH cells were identified as
CD4+Gr1-CXCR5+PD-1+ by flow cytometry as previously described (212).

3.2.6 Immunofluorescence staining
Two-millimeter slices of spleens were taken from mice on days 3, 5, 7, and 14
postimmunization and quick-frozen horizontally in OCT (Tissue-Tek, Sakura, CA). Fivemicrometer sections were prepared and stained with biotinylated anti–GL-7/streptavidinconjugated allophycocyanin and Pacific Blue–conjugated anti-B220 (all from
eBioscience). Images were collected using an HC Plan Apo 103/0.7NA objective lens on
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a Leica DMR upright microscope (Leica Microsystems) equipped with a Retiga EXi
Cooled CCD Camera (QImaging). Numbers of GCs were counted from three distinct
fields per spleen and the average number was used for statistical analyses.

3.2.7 Statistical analyses
All statistical analyses were performed using GraphPad Prism version 4.00 for Windows,
GraphPad Software (San Diego, CA; http://www.graphpad. com). Statistical significance
between the means of two groups was determined using Student t test or the
nonparametric Mann–Whitney U test as applicable. Analyses of in vivo kinetics of TFH
and GC B cells were done by two-way ANOVA tests. Analysis of Gr1+ cell– mediated
suppression of TFH differentiation in vitro was done using the one-way ANOVA test.

3.3. Results

3.3.1 Female (NZB x NZW)F1 mice produce more Ab in response to immunization
than male (NZB x NZW)F1 mice
To determine whether male and female (NZB x NZW)F1 mice responded differently to
Ag challenge, 9-wk-old mice were immunized i.p. with NP-CGG/CFA known to elicit a
strong T-dependent IgG1 response (213). Four weeks post-immunization (day 28), female
(NZB x NZW)F1 mice produced significantly higher titers of anti-NP–specific IgG1 Abs
(p < 0.001) than male (NZB x NZW)F1 mice (Figure 3.1A). In a separate study, we
determined the numbers of splenic GC B cells and PCs in male and female (NZB x
NZW)F1 mice 2 wk post-immunization (day 14). Female (NZB x NZW)F1 mice
expressed significantly elevated numbers of splenic GL-7+B220+CD38low GC B cells (p <
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0.05) and CD138+B220low IgMlow PCs (p < 0.05) as compared with male (NZB x
NZW)F1 mice (Figure 3.1B, 3.1C).

Figure 3.1 Female (NZB x NZW)F1 mice have stronger Ab responses than males in
response to T dependent Ag. (A) Male and female (NZB x NZW) F1 mice were
immunized at day 0 with 20 µg NP27- CGG in CFA or control PBS. (A) On day 28, mice
were analyzed for serum anti-NP5 IgG1 Abs by ELISA. ***p < 0.001, Student t test. (B
and C) A separate cohort of mice were immunized as in (A) and euthanized on day 14.
Total number of splenic GL7+ GC B cells and CD138+B220low PCs were enumerated.
Each symbol represents one mouse. *p < 0.05, Mann–Whitney U test.
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3.3.2. Gr1+ cells suppress Ab responses to T-dependent Ag challenge in male but not
female (NZB x NZW) F1 mice
We have previously shown that male (NZB x NZW) F1 mice have constitutively higher
levels of Gr1+CD11b+ cells, and that depletion of Gr1+ cells in vivo reduces the levels of
antinuclear Abs in male but not female (NZB x NZW)F1 mice (211). To determine
whether Gr1+ cells play a similar role in the NP-CGG/CFA–induced Ab response, we
treated male and female (NZB x NZW)F1 mice with anti-Gr1–depleting Abs or control
rat IgG Abs continuously every 3 d starting 1 d before immunization. Treatment with
anti-Gr1–depleting Ab did not significantly affect other cell populations (Figure 3.2A).
As expected, depletion of Gr1- expressing cells elevated the anti-NP–specific IgG1 Ab
titers in male mice as compared with control rat IgG-treated males (p < 0.001; Figure
3.2B), whereas depletion of Gr1-expressing cells had no significant effect on the Ab
response in female mice (p = 0.17; Figure 3.2C). When analyzing the splenic
compartment at 2 wk post-immunization we found that depletion of Gr1-expressing cells
resulted in higher numbers of both GC B cells and PCs in male mice (p < 0.05), but again
with no

effect in female mice (Figure 3.2D, 3.2E). Notably, consistent with their

autoimmune phenotype, unimmunized female (NZB x NZW)F1 mice expressed
continuously increased numbers of PCs as compared with male (NZB x NZW)F1 mice (p
< 0.05; Figure 3.2E). Thus, Gr1-expressing cells suppress immunization-induced Ab
responses in male, but not female, mice.
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Figure 3.2(A) Treatment with anti-Gr1–depleting Ab did not significantly affect
other cell populations. Injection of Anti-Gr1 depletion antibody does not affect nonGr1- expressing cell subsets in the spleen. Male (NZB x NZW)F1 mice were injected
with 500 μg anti-Gr1 antibody (column 2 and 4) or 500 μg rat IgG control antibody
(column 1 and 3). After 48 hours, spleens were harvested and the relative levels of
lymphoid- and myeloid derived cell subsets were defined by flow cytometry.
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C

D

E

Figure 3.2(B-E) Depletion of Gr1+ cells augments Ab responses after TD-Ag
immunization. Male and female (NZB x NZW)F1 mice were immunized at day 0 with
20 μg NP27-CGG in CFA. Where indicated, mice were additionally treated with an antiGr1–depleting Ab or control rat IgG every 3 d starting at day -1. Serum from males (B)
and females (C) was collected every 7 d and tested for levels of anti-NP5 IgG1 Abs by
ELISA. An asterisk above the graph indicates statistical difference at a single time point
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(Student t test), whereas the p value inserted at the lower right of the graph denotes the
statistical difference between anti-Gr1 Ab and control IgG–treated mice over time (twoway ANOVA test). (D and E) A separate cohort of mice were immunized and treated as
in (B) and (C), but sacrificed at day 14 post-immunization. Splenic GC B cells (D) and
PCs (E) were assessed by flow cytometry. n = 5–9/ treatment group. *p < 0.05, Mann–
Whitney U test.
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3.3.3 Gr1+ cells suppress Ab responses only to T-dependent Ag challenge in male
(NZB x NZW) F1 mice
To determine whether the suppressive effect was dependent on T cells, an additional
cohort of male (NZB x NZW)F1 mice was immunized with NP-Ficoll, a T-independent
Ag, and treated with either depleting anti-Gr1 Ab or rat IgG control Ab. Depletion of
Gr1-expressing cells had no effect on the Ab response and B cell differentiation induced
after T-independent Ag immunization (Figure 3.3A). Also there was no difference in the
numbers of GC B cells and PCs between anti-Gr1 Ab or rat IgG control Ab treated
animals (Figure 3.3B, 3.3C). Thus, the in vivo suppressive effect of Gr1+ cells is
dependent on T cells.

A

B

C

Figure 3.3 The T-independent immune response in not regulated by Gr1+ cells in
male (NZB x NZW)F1 mice. Male (NZB x NZW)F1 mice were immunized with NP27FICOLL/CFA on day 0. Mice were treated with depleting anti-Gr1 Ab (n = 4) or control
rat IgG (n = 4) every three days starting on day -1. Serum was obtained every 7 days and
tested for anti-NP antibodies (A). Total numbers of GC B cells (B) and PCs (C) were
enumerated from spleens of treated mice upon sacrifice on day 28.
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3.3.4 Male, but not female, Gr1low CD11b+ cells suppress T cell proliferation in vitro
Gr1-expressing cells consist of two major cell subsets expressing high and low levels of
Gr1, respectively. Both subsets have been shown to have suppressive functions in cancer
studies (reviewed in Ref. (175)); however, Gr1lowLy6C+CD11b+ cells have been
specifically associated with T cell suppression in another model of lupus (214). We
hypothesized that Gr1lowCD11b+ cells from male (NZB x NZW)F1 mice could have a
similar suppressive effect on T cells and hence be involved in the in vivo effect of Gr1 +
cells during T-dependent Ab responses. Gr1highCD11b+ and Gr1low CD11b+ cells were
sort purified from male and female 4-wk-old (NZB x NZW)F1 mice (Figure 3.4A) and
added to CFSE-labeled MACS-purified T cells in the presence or absence of anti-CD3
and anti-CD28 cross-linking Abs. Gr1lowCD11b+ cells, but not Gr1high CD11b+ cells,
suppressed T cell proliferation in vitro (Figure 3.4B, 3.4C). Although both male- and
female-derived Gr1lowCD11b+ cells from 4-wk-old mice functionally suppressed T cell
proliferation, only suppression by male-derived cells reached statistical significance
(male: p < 0.01; female: p = 0.056; Figure 3.4D). This difference became even more
apparent when we compared the suppressive effect of male and female Gr1lowCD11b+
cells obtained from 9-wk-old (NZB x NZW)F1 mice (Figure 3.4E), and is consistent with
the differential effect of in vivo Gr1+ cell depletion in 9-wkold male and female (NZB x
NZW)F1 mice as described earlier (Figure 3.2).
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Figure 3.4 Male, but not female, Gr1lowCD11b+ cells from 9-wk-old (NZB x NZW)F1
suppress T cell proliferation in vitro. (A) Gating strategy for flow cytometry–based
isolation of Gr1highCD11b+ and Gr1lowCD11b+ cells. Both populations of cells reached
>99% purity after isolation. (B) The identification of CFSE-labeled CD4+ T cells after 2
d of culture either unstimulated (none) or stimulated (anti-CD3/CD28). (C) Histogram
plots showing the percentage of CD4+ cells that underwent >1 divisions in culture (gate:
dividing cells) in the presence or absence of anti-CD3/anti-CD28 stimulation and Gr1high
CD11b+ or Gr1lowCD11b+ cells (4:1 ratio of T cells to Gr1+ cells). (D) The average of five
independent experiments (mean ± SEM) using cells from 4-wkold mice is shown. **p <
0.01, paired Student t test. (E) Gr1lowCD11b+ cells from male (NZB x NZW)F1 mice
remain suppressive in 9-wk-old mice, whereas female-derived Gr1lowCD11b+ cells lose
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their capacity to suppress. Experiments were done as shown in (A)–(D). Bars show the
mean ± SEM of six independent analyses. *p < 0.05, **p < 0.01, paired Student t test.

3.3.5 Depletion of Gr1-expressing cells during immunization of male (NZB x
NZW)F1 mice alters the distribution of CD4+ effector T cell subsets
Because the suppressive effect of Gr1-expressing cells after immunization is dependent
on T cells, and Gr1lowCD11b+ cells specifically suppress T cell proliferation in vitro, we
expected T cells to be differentially expressed in immunized male (NZB x NZW)F1 mice
treated with anti-Gr1–depleting Ab or control rat IgG. Contrary to our prediction, total
numbers of both CD4+ and CD8+ T cells were unaffected by the absence of Gr1+ cells
(Figure 3.5A, 3.5B). Further analyses showed that the percentage of CD4+ T cells
expressing markers consistent with memory-effector T cells (CD44highCD62Llow), TFH
cells (ICOS+PD-1+CD4+) were significantly increased in the absence of Gr1-expressing
cells (p < 0.001, p < 0.01, respectively; Figure 3.5C). T regulatory cells
(Foxp3+CD4+CD25+) were also increased in Gr1+ cell–depleted mice as compared to
non-depleted mice, but the difference failed to reach statistical significance (p =0.056). In
contrast, the percentage of naive CD4+ T cells (CD44low CD62Lhigh) significantly
decreased (p < 0.01) after Gr1+ cell depletion (Figure 3.5C). Thus, Gr1+ cells appear to
regulate differentiation of CD4+ T cells during thymus-dependent (TD) Ab responses in
vivo.
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Figure 3.5 Depletion of Gr1+ cells affects CD4+ T cell subsets after antigen
immunization in male (NZB X NZW)F1 mice. Male (NZB x NZW)F1 mice were
immunized with NP27-CGG in CFA on day 0 and treated with either anti-Gr1 depleting
antibody or control rat IgG every three days starting at day -1. Mice were sacrificed 14
days post immunization and numbers of splenic CD4+ T cells (A) and CD8+ T cells (B)
were determined. (C) Activation and differentiation of CD4+ T cells were analyzed by
flow

cytometry:
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FoxP3+CD4+CD25+. Each symbol represents one mouse. n = 6-7. * p < 0.05; ** p < 0.01;
*** p < 0.001, Mann-Whitney U test.
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3.3.6 Gr1-expressing cells inhibit GC formation after Ag challenge
GC formation is crucial for class switching and production of Abs after immunization,
and is dependent on T cell help, specifically TFH cells. The increased number of GC B
cells (Figure 3.2C) and TFH cells (Figure 3.5C) in anti-Gr1 Ab–treated male (NZB x
NZW)F1 mice 14 d post-immunization suggest that Gr1-expressing cells may also affect
GC reactions. We tested this by comparing the number of T FH cells and GC B cells, and
the appearance of GCs in mice immunized with NP-CGG/CFA and treated with either
depleting anti-Gr1 Ab or control rat IgG. Already at 5 d post-immunization, mice
depleted of Gr1-expressing cells expressed elevated levels of TFH cells, and at 7 and 14 d
post-immunization, the levels were significantly higher in anti-Gr1 Ab–treated mice
(Figure 3.6A). Numbers of splenic GC B cells were similarly elevated in mice depleted of
Gr1-expressing cells 14 d post immunization (p < 0.01; Figure 3.6B). These data were
further supported by immunofluorescence staining of spleen sections showing
significantly elevated numbers and increased sizes of GCs in anti-Gr1 Ab–treated mice
(Figure 3.6C, 3.6D).
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Figure 3.6 Depletion of Gr1+ cells enhances TFH cell differentiation and GC
formation in vivo. (A and B) Male (NZB x NZW)F1 mice were immunized as described
in Figure 3.1. Mice were additionally treated with anti-Gr1 depleting antibody or control
rat IgG at days -1, 2, 4 and 6. Cohorts of mice were sacrificed at days 3, 5, 7, and 14 and
analyzed for numbers of splenic TFH cells (CD4+PD-1+CXCR5+)(A) and GC B cells
(GL7+B220+)(B). Numbers of TFH cells were compared per time point: * p < 0.05; ** p
< 0.01; *** p < 0.001, Mann-Whitney U test. (C) Snap-frozen spleen sections from the
same mice were stained for GC using biotinylated GL7/streptavidin-allophycocyanin
(APC) and Pacific Blue-conjugated B220. Original magnification X10. (D) Numbers of
GCs per field of vision were quantified by averaging the count from 3 distinct fields per
spleen. n = 3-9 per time/point. * p < 0.05; ** p < 0.01; *** p < 0.001.
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3.3.7 Male (NZB x NZW)F1 Gr1-expressing cells suppress T cell differentiation into
TFH cells in vitro
TFH cells play a major role in the formation of GC. Because numbers of TFH cells, GC B
cells, GCs, and PCs were all significantly upregulated in the absence of Gr1-expressing
cells, we asked whether Gr1+ cells can directly suppress differentiation of naive T cells
into TFH cells in vitro. Sort-purified male (NZB x NZW)F1 naive T cells
(CD90.2+CD62Lhigh) were cocultured with increasing concentrations of sort-purified
male Gr1+ cells for 5 d in TFH cell-skewing media (Figure 3.7A, 3.7B) (212). Upon
harvest, cells were stained for Gr1, CD4, CXCR5, and PD-1, and the percentage of
CXCR5, PD-1, double-positive CD4+ cells was determined as previously described
(212). Gr1+ cells significantly suppressed the differentiation of naive T cells into TFH
cells. The suppression was dose dependent and reached statistical significance at 4:1 and
8:1 ratios of T cells to Gr1+ cells (p < 0.01). The suppression of differentiation was not
due to reduced survival of T cells, as the number of CD4+ T cells recovered on day 5
improved significantly and in a dose-dependent manner with the addition of Gr1+ cells
(p< 0.05–0.001; data not shown). Thus, immunosuppressive Gr1+ cells appear to play a
hitherto unrecognized role in controlling naive T cell differentiation during T-dependent
Ag exposure.
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Figure 3.7 Male (NZB x NZW)F1 Gr1+ cells inhibit naïve T cell differentiation into
TFH cells in vitro. (A) Naïve CD4+ T cells (CD90+CD62Lhigh) and total Gr1+CD11b+ cells
were flow sorted from 9 wk old male (NZB x NZW)F1 mice by flow cytometry. (B) T
cells were plated in TFH-skewing media alone or in the presence of Gr1+CD11b+ cells at
the indicated ratios. After 5 days, cells were harvested and stained for CD4, CXCR5 and
PD-1, indicating a TFH-like phenotype. All cells analyzed were Gr1-. The contour plots
shown are representative of four independent experiments. The mean ± SD per condition
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is shown in the upper right corner of each plot. The p value given in each plot indicates
the statistical difference between T cells differentiated in the presence or absence of Gr1+
cells (one-way ANOVA test).
3.4 Discussion
The sex bias in SLE and other autoimmune diseases is not well understood. There is
evidence that sex hormones, both estrogen and testosterone, are involved in the
differential prevalence of SLE and mouse lupus-like disease among males and females
(70,72,73,81,169,170). The protective function of testosterone, although well established,
has not been studied in details and the molecular mechanism through which male sex
hormone may act is not known. Interestingly, Ab responses to immunization are often
also higher in females than in males (reviewed in Ref.(210)), suggesting that a generally
overactive immune system in females might exist and help explain the female sex bias
observed in many autoimmune disorders, including SLE.
We have recently shown that male lupus-prone (NZB x NZW) F1 mice have higher
levels of immunosuppressive Gr1+ cells than females, that these cells are driven by
testosterone, and that depletion of the cells in males resulted in increased spontaneous
autoantibody production (211). Using the same model, in this article, we describe how
male (NZB x NZW)F1 mice respond less vigorously than females to TD exogenous Ag
immunization. Furthermore, depletion of Gr1+ cells in (NZB x NZW)F1 males increased
the Ab response to Ag challenge, along with an underlying expansion of splenic GC B
cells, PCs, and TFH cells. The main function of T FH cells is to facilitate GC reactions and
the differentiation of naïve B cells into PCs. Interestingly; T FH cells have been associated
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with disease severity in lupus patients, as well as several murine models
(154,161,207,215-218). Thus, we hypothesized that Gr1+ cells control Ab production
primarily via modulation of TFH cells. In support hereof, we found that Gr1+ cells
inhibited the differentiation of TFH cells in vitro in a dose-dependent manner, although
the mechanism of suppression remains unresolved.
Gr1+ cells are a heterogeneous population of cells consisting of mature and immature
neutrophils, immature monocytes, and some dendritic cell subsets. Both proinflammatory
and suppressor functions have been associated with such cells. In cancer,
immunosuppressive Gr1+ cells are widely known as myeloid-derived suppressor cells
(MDSCs; reviewed in Ref.(175)). Despite the identification of immunosuppressive Gr1+
cells in several models of autoimmunity (125,126,219-221), during viral infections (123),
and graft rejection (222), the term MDSC is only sporadically used in such models.
Whether testosterone-induced Gr1-expressing cells from male (NZB x NZW)F1 mice can
be classified as MDSCs or represent a different population of immunosuppressive Gr1expressing cells in this lupus model remains to be determined. The observation that male
Gr1highCD11b+ cells suppress B cells independent of reactive oxygen species, NO, IL-10,
and TGF-β (211) suggests the cells may not reflect tumor-induced MDSCs (121,223),
although further molecular and functional studies directly comparing these cell subsets
are needed to confirm such distinction.
In nonautoimmune C57BL/6 mice, Gr1-expressing cells have also been shown to affect
the activation of adaptive immunity after footpad immunizations (224). Specifically, it
was shown that neutrophils (defined as Gr1+Ly-6G+CD11b+) interfered with the
activation of T cells through the control of Ag uptake by professional APCs, thereby
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limiting dendritic cell–T cell contact time in draining lymph nodes (224). Interestingly,
analyses of Gr1+ cells in nonautoimmune mouse strains revealed similarly elevated levels
in males of most strains, including C57BL/6 (B6), BALB/c, and 129/Sv (data not shown).
Upon immunization with NP-CGG in CFA, we detected increased serum Ab responses in
female as compared with male B6 mice (data not shown). Interestingly, preliminary
analyses showed that Ab-mediated depletion of Gr1+ cells in B6 mice drove expansions
of GC and memory B cells in spleens of both male and female C57BL/6 mice 4 wk after
immunization, albeit without affecting anti-NP–specific Ab levels (E. Der and T.N.
Jorgensen, unpublished observations). Thus, Gr1+ cells from nonautoimmune B6 mice
may exert some, but not all, of the immunosuppressive functions we observe in (NZB x
NZW)F1 mice.

Interestingly, for reasons yet unknown, Gr1-expressing cells seem to have a limited
protective effect in females (Ref. (211)) and this study). In fact, upon aging or during
active disease, female Gr1+ cells become stimulatory as described by us and others
(113,211,225,226), suggesting that disease-related inflammatory factors present in lupusprone females can influence the immunosuppressive function of immature myeloid Gr1+
cells. Identification of such factor(s) clearly represents an attractive new target for
therapeutic use in SLE and other diseases with dysregulated Ab production.
In summary, Gr1-expressing cells from lupus-prone male (NZB x NZW)F1 mice
suppress T and B cell responses, resulting in reduced GC formation and less PC
differentiation. Discovering the mechanism through which Gr1+CD11b+ cells suppress in
the context of lupus could open new doors for immunotherapy of lupus patients and new
targets for therapeutic agents.
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CHAPTER IV

INTRINSIC AUTOIMMUNE CAPACITIES OF HEMATOPOIETIC CELLS
FROM FEMALE NEW ZEALAND HYBRID MICE

Abstract
Most systemic autoimmune diseases are more commonly found in females than in males.
This is particularly evident in Sjögren’s Syndrome, Systemic Lupus Erythromatosis
(SLE) and thyroid autoimmunity, where the ratio of females to males ranges from 20:1 to
8:1. Our understanding of the etiology of SLE implies important roles for genetics,
environmental factors as well as sex hormones, but the relative significance of each
remains unknown. Using the New Zealand hybrid mouse model system of SLE we
present here new fetal liver chimeras –based system in which we can segregate the effects
of immune system genes and sex hormones in vivo. We show that female hematopoietic
cells express an intrinsic capacity to drive lupus-like disease in both male and female
recipient mice, suggesting that this capacity is hormone independent. Particularly, only
chimera mice with a female hematopoietic system showed significantly increased
numbers of germinal center B cells, memory B cells and plasma cells followed by a
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spontaneous loss of tolerance to nuclear components and hence elevated serum antinuclear autoantibodies. A protective effect of testosterone was noted with regards to
disease onset, not disease incidence. Thus, genetic factors encoded within the female
hematopoietic system can effectively drive lupus-like disease even in male recipients.

4.1 Introduction
Autoimmune diseases such as systemic lupus erythematosus (SLE) have a strong female
bias (64). A female predominance is also observed in the New Zealand hybrid mouse
model of SLE ((NZB x NZW)F1), where 100% of females, but less than 40% of males
develop end-stage renal disease within 1 year of age (70,71) . Lupus-like disease in (NZB
x NZW)F1 mice is characterized by elevated anti-nuclear autoantibodies (ANA), IgGimmune complex (IgG-IC) deposition and complement fixation in the kidney glomeruli,
and glomerulonephritis (GN) resembling the human disorder (227). The disease is
generally believed to be mediated by immune system defects as shown in bone marrow
(BM) transfer studies (228).
Levels of sex hormones or differences in sex-linked gene expression patterns are valid
explanations for the pronounced sex difference observed (NZB x NZW)F1 lupus-like
disease. In this regard, prepubertal hormonal manipulation studies have shown a
protective effect of testosterone and exacerbating effect of estrogens (70,72,73,81,208).
In addition, exposure to sex hormones during embryogenesis can affect autoimmune
development in adult mice (229).
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Genetic overexpression of X-linked genes, as seen in mice carrying the Yaa lupus
susceptibility locus, has also been strongly associated with disease development
(161,230). Particularly, a link between copies of Tlr7 and the development of ANA have
been demonstrated (161,231-233), although other genes expressed on the X chromosome
likely also play a role, as demonstrated in TLR7-deficient male B6.Nba2(Yaa) congenic
lupus-prone mice (234). Also supporting an effect of the X chromosome are data showing
a correlation between pristine-induced lupus-like disease and X chromosome dosage in
castrated Sry-transgenic male mice and the accelerated spontaneous development of
lupus in XX versus XY- NZM2328 mice (157).
Type I interferons (IFNα) play a crucial role in SLE and lupus-like disease development
(187,235). In (NZB x NZW)F1 mice, elevating the levels of IFNα increases autoantibody
production and accelerates renal disease onset (236). IFNα can be produced by many cell
subsets, but most noticeably by plasmacytoid dendritic cells (pDCs) in response to a
variety of stimuli targeting intracellular toll-like receptors (TLR) 7, 8 and 9 and
cytoplasmic DNA sensors such as Aim2, DAI/ZBP1, Lrrfip1 and IFI16 (Ifi204) (237240). IFNα is known to affect T cells, as well as B cells, although whether one or both
mechanisms are involved in IFNα-driven lupus-like disease is still unknown (241,242).
In this study, we investigated whether female hematopoietic stem- and progenitor cells
were capable of driving autoimmunity in the presence of male and/or female sex
hormones. Using a unique mixed sex chimera system, we found that female
hematopoietic cells (HCs) could drive the development of lupus-like renal disease,
elevated levels of germinal center (GC) B cells, memory B cells and plasma cells, and
increased ANA in all recipients regardless of sex hormone levels. In addition, mice
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receiving female HCs expressed elevated levels of serum IFNα prior to the generation of
ANA and the onset of renal disease. Male recipients of female HCs exhibited a delay in
the onset of disease as compared with female recipients, suggesting that the protective
effect of testosterone affected early events in disease propagation only. Thus, surprisingly
the disease-driving capacity of female HCs appears more potent in driving disease than
the known protective effect of testosterone.
4.2 Materials and Methods

4.2.1 Mice and cells
Three week old male and female (NZB x NZW)F1 mice were obtained from The Jackson
Laboratory and kept in a specific pathogen-free environment at National Jewish Health
(Denver, CO, USA). All mouse experiments were approved by the local IACUC
committee. Bone Marrow chimera mice were generated by lethal irradiation (1000 rad)
using a Cs137-irradiator of 4 wk old male or female prepubertal (NZB x NZW)F1 mice.
Mice were given acidified water (pH 2.7) to drink throughout the experiment. Bone
marrow cells were obtained from 4 wk old male or female (NZB x NZW)F1 mice and
5x106 cells were injected intravenously 2-4 hours after irradiation. Fetal liver single cells
were obtained from E13.5-E14.5 embryos and frozen in 90% fetal bovine serum, 10%
DMSO at -80°C. The sex of each embryo was determined visually as well as by real-time
RT-PCR analyses of Uty and Xist expression levels (see below). Each fetal liver provided
enough cells to reconstitute 3 recipients via tail vein injection.
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4.2.2 Real-time reverse transcriptase-polymerase chain reaction
PBMCs were obtained from chimera mice 6 weeks post reconstitution. RNA was isolated
using RNeasy Plus Micro Kit (Qiagen, Valencia, CA, USA) and cDNA prepared using
the qScript cDNA SuperMix (Quanta BioSciences, Gaithersburg, MD, USA). PCR was
run on a real-time PCR machine (ABI7300, Applied Biosystems, Carlsbad, CA, USA)
using the following primers: Xist-F: 5’-GGAGGAACGAAAGACCAAATTG-3’; Xist-R:
5’-GTCCCACCCTCTGT

GAGTGAA-3’;

Uty-F:

5’-

TGCCATCACAAGTCAAAGCAA-3’; Uty-R: 5’-TGGTGCATCCA ACCTAACTGTT3’. Unmanipulated male and female samples were used separately or in different ratios
(1:1, 1:3, 1:9, 1:27) to generate a standard curve. The levels of transcripts in chimera
mice were calculated as % of total.

4.2.3 Detection of sex hormones
Estradiol and testosterone were measured by ELISA using the manufacturer’s protocols
(US Biological, Salem, MA, USA). Testosterone levels were measured on 10 times
diluted serum. Estradiol levels were measured after extraction. Briefly, 50 µl of serum
was vortexed with 500 µl ethyl ether for 30 seconds. Phases were allowed to separate and
the organic phase was transferred to a fresh glass tube. Solvent was allowed to evaporate
before the residue was dissolved in 250 µl of extraction buffer.

4.2.4 Antibody ELISA
Serum was obtained from chimera mice every 4 weeks starting 8 weeks post irradiation
and reconstitution. For detection of total IgG and IgM, serum was diluted 1:50.000–
1:200.000 in serum diluent (sterile filtered 0.5% bovine -globulin, 5% gelatin, 0.05mM
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Tween in 1x PBS). For detection of ANAs, serum was diluted 1:300. Levels of antichromatin, anti-histone and anti-dsDNA IgG autoantibodies were measured as previously
described (211). All reactions were developed using 10mg/ml 2,2'-azino-bis(3ethylbenzothiazoline-6-sulphonic acid)(ABTS) in McllWain’s buffer (0.09 M Na2HPO4,
0.06 M citric acid, pH 4.6). Anti-dsDNA IgG levels were determined using the
manufacturer’s protocol (Alpha Diagnostic International Inc., San Antonio, TX, USA).

4.2.5 Cytokine ELISA
IFNα and BAFF were measured in 1:4 diluted serum obtained 12 and 16 weeks post
irradiation and reconstitution, respectively, using the manufacturer’s protocols (IFNα
ELISA: PBL Interferon Source, NJ; BAFF ELISA: R & D Systems, Minneapolis, MN,
USA).

4.2.6 Flow Cytometry
Flow cytometry was performed using a Cyan Flow cytometer ADP (BECKMAN
COULTER, Indianapolis, IN, USA) and all analyses were done using FloJo version 9.5.2
(Tree Star Inc., Ashland, OR, USA). Antibodies with the following specificities were
used for all analyses: CD11b, CD11c, CD19, CD21, CD23, CD38, CD40, B220
(CD45R), CD86, CD138, F4/80, Gr1 (Ly6C/6G), IgM, IgD, (all from eBiosciences, San
Diego, CA, USA). Peanut agglutinin (PNA) was obtained from Vector inc. (Burlingame,
CA, USA).
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4.2.7 Immunofluorescence staining
IgG deposition and complement factor 3 (C3) fixation was measured by
immunofluorescence staining. Briefly, half kidneys were quick-frozen in OCT and 5µm
sections were prepared. Sections were stained using TexasRed-conjugated anti-mouse
IgG (Invitrogen, Grand Island, NY, USA) and FITC-conjugated anti-mouse C3 specific
antibodies (ICL Inc., Portland, OR, USA). Images were collected using an HC Plan Apo
20x/0.7NA objective lens on a Leica DMR upright microscope (Leica Microsytems,
Buffalo Grove, IL, USA) equipped with a Retiga EXi Cooled CCD Camera (QImaging,
Surrey, BC, Canada).

4.2.8 Statistical analysis
All statistical analyses were done using GraphPad Prism v. 5.04 (GraphPad INC., La
Jolla, CA, USA). Analyses of cumulative incidence were done using a Log-rank test
(Mantel Cox test). Comparisons of average time of onset, cellular proportions, and serum
cytokine levels between two groups were done using a two-tailed non-parametric Mann
Whitney test. P values < 0.05 were considered statistical.

4.3 Results

4.3.1 Female BM cells transfer renal disease into male and female recipients with a
higher incidence and faster kinetic than male BM cells
Estrogens are known to promote lupus-like disease development in (NZB x NZW)F1
mice, while testosterone has been found to protect against the disease (72,73). In
addition, X chromosome dosage has been found to affect disease development in other
mouse models of SLE (157,243) . Since sex hormones affect the immune system
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(76,244), distinguishing the effect of hormones from the effect of genes has been
challenging. We asked if female HCs from (NZB x NZW)F1 mice could transfer disease
into hormonally intact, lethally irradiated, age-matched male recipients. The major male
antigen H-Y is not presented by H2d and H2z, allowing reconstitution to occur without
rejection (245).To avoid potential effects of pubertal sex hormones, we performed the
experiments using 4 wk old, prepubertal mice. Female HCs were capable of driving
lupus-like renal disease in 100% of recipient mice by 31 wks post transfer, regardless of
the sex of the recipient mouse (Figure 4.1A). In contrast, within the same timeframe,
male HCs transferred disease into 57% and 25% of female and male recipients,
respectively (Figure 4.1A, p < 0.05-0.001). Even when kept until 1 year of age (48 weeks
post transfer), only ~85% of recipient mice accepting male hematopoietic cells developed
renal disease (p<0.001). Irradiation and reconstitution itself accelerated end-stage lupuslike disease development in all recipient mice regardless of sex, although the
characteristic difference between control male-into-male and female-into-female
remained statistically significant (p < 0.001). The disease onset was similar in male and
female mice receiving female BM cells, while M-into-M BM chimera mice started
developing disease slightly later than M-into-F BM chimera mice (Figure 4.1A, not
statistically significant).

The differential disease development was not driven by differences within the stem cell
and progenitor cell compartment of males and females, as BM samples from 4 wk old
unmanipulated male and female (NZB x NZW)F1 mice showed equivalent levels of
hematopoietic stem cells (HSC), common myeloid progenitors (CMP), common
lymphoid

progenitors

(CLP),

granulocyte-macrophage
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progenitors

(GMP)

and

megakaryocyte-erythrocyte progenitors (MEP) (Figure 4.1B). In addition, all mice
analyzed had grafted successfully, as noted by the relative expression of Xist and Uty
transcripts in PBMC fractions from mice receiving female or male hematopoietic cells
(Figure 4.1C). Moreover, recipient mice continued to express sex hormones at levels
equivalent to unmanipulated mice as determined by serum levels of estradiol and
testosterone (Figure 4.1D-E). Thus, female HCs from prepubertal 4 wk old (NZB x
NZW)F1 mice transferred accelerated renal disease into both male and female agematched (NZB x NZW)F1 mice independently of the recipient’s sex hormone
environment.

Figure 4.1 Female prepubertal BM cells transfer lupus-like disease in a hormone
independent fashion. Four wk old (NZBxNZW)F1 male and female mice were lethally
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irradiated and reconstituted with male or female BM cells from age-matched mice. (A)
Mice were followed for the development of renal disease by detection of proteinuria
every two weeks. Mice with severe proteinuria (> 100mg/dL on two consecutive
readings) were considered positive. All mice were euthanized 48 weeks post transfer,
regardless of disease stage. Female-into-female (open square, n=6); Female-into-Male
(light grey triangle, n=8); Male-into-female (dark grey triangle, n=7); Male-into-Male
(filled circle, n=8). (B) BM cells were isolated from 4 wk old mice (n=5 for both males
and females) and the proportions of hematopoietic stem cells and progenitor cell subsets
were determined by flow cytometry. (C) PBMCs were isolated from BM chimera mice
18 weeks after transfer (n=2 of each). Total RNA was isolated and cDNA generated. The
levels of Xist and Uty transcripts were normalized to the levels of beta-2-microglobulin
and the % was calculated relative to the levels in control female-into-female (100% Xist)
or male-into-male (100% Uty) BM chimera mice. (D and E) Serum was isolated from
BM chimera mice 18 weeks after transfer and levels of testosterone (D) and estradiol (E)
were measured by ELISA. Female recipient: n=13 (testosterone), n=6 (estradiol); male
recipient: n=15 (testosterone), n=5 (estradiol); female control: n=10 (testosterone), n=10
(estradiol); male control: n=6 (testosterone), n¼7 (estradiol). *** p < 0.001.
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4.3.2 The capacity of female hematopoietic cells to transfer renal disease is present
in utero
Sex hormones are produced at high levels starting at puberty. However, even in utero and
during the postnatal period sex hormones are produced, and hence HCs from 4-week-old
female (NZBxNZW)F1 mice could have acquired their autoimmune capacities as a result
of such exposure. To test for this possibility, we generated fetal liver (FL) mixed chimera
mice. FL cells were isolated from male or female (NZBxNZW)F1 embryos at days
E13.5–E14.5 and transferred into lethally irradiated 4-week-old prepubertal male or
female (NZBxNZW)F1 mice. Mice were followed for the development of proteinuria
until 32 weeks after transfer. Diagnosis of disease was confirmed by discovery of
elevated colocalized IgG-immune complex deposition and complement fixation in kidney
glomeruli in chimera mice that had received female FL cells (Figure 4.2D).

Similar to the experiments involving BM cell transfer from 4-week-old donors, female
FL cells induced a rapid onset of disease in 100% of recipient mice, while male FL cells
induced less disease and significantly delayed disease onset (Figures 4.2A and B,
p<0.001). However, disease occurred somewhat later in male, versus female, recipients of
female FL cells (Figure 4.2B, p<0.01). Again, we did not find this to be a result of
differences among the transferred HCs, as analyses of FL cells from male and female
(NZBxNZW)F1 embryos showed no differences in the distribution of cell subsets (Figure
4.2C). Similar to the BM chimeric mice, serum level of sex hormones in FL chimeric
mice were comparable to that of unmanipulated male and female (NZBxNZW)F1 mice
(data not shown).
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Figure 4.2 Female FL cells transfer lupus-like disease into both male and female
recipients with 100% incidence. Four week old BWF1 male and female mice were
lethally irradiated and reconstituted with male or female FL cells from E14.5 male or
female (NZBxNZW)F1 embryos. (A) Two cohorts of FL chimera mice were followed for
the development of renal disease by detection of proteinuria every 2 weeks. Mice with
severe proteinuria (> 100mg/dL on two consecutive readings) were considered positive.
All mice were euthanized 35 (cohort 1) or 32 (cohort 2) weeks after transfer, regardless
of disease stage. Female-into-female (open square, n = 10); female-into-male (light grey
triangle, n = 12); Male-into-female (dark grey triangle, n = 7); Male-into-male (filled
circle, n = 4). (B) Disease onset up to 35 weeks after transfer (cohort 1) is shown.
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Female-into-female (open square, n=5); female-into-male (light gray triangle, n=5);
male-into-female (dark gray triangle, n=7); male-into-male (filled circle, n=4). Control
unmanipulated mice are included for comparison: females (open diamonds, n=6) and
males (filled diamonds, n=6). (C) FL cells were isolated from E14.5 embryos and the
ratios of stem cell and progenitor cell subsets were determined in male cells (filled
squares, n=4) and female cells (open triangles, n=6). NS: not statistically different. (D)
Upon sacrifice of the mice described in (A), kidneys were harvested and analyzed for IgG
deposition (red) and C3 fixation (green). Pictures shown represent averages per
condition. Each symbol represents an individual mouse. * p < 0.05; ** p < 0.01; *** p <
0.001.

4.3.3 Reconstitution with Female FL cells specifically affects levels of post-activation
B cell subsets
Lupus is a B cell and autoantibody mediated disorder. We tested if B cell numbers and
subset distribution were different between the four groups of FL chimera mice. Gating
strategies are depicted in Figures 4.3A-D. In spleens, neither total numbers of B cells
(CD19+) nor marginal zone B cells (CD19+CD21highCD23-IgMhighIgDlow) were
significantly different between various FL chimera mice (Figure 4.3 E and G). However,
mice that had received female FL cells displayed overall increased levels of follicular
mature B cells (CD19+CD21lowCD23highIgMlowIgDhigh) (Figure 4.3F), regardless of the
sex of the recipient. Even more strikingly, numbers of germinal center B cells
(CD19+PNA+CD38lowIgMlow), memory B cells (CD19+CD38hiIgMlow) and plasma cells
(B220low/negCD138+IgM-) were significantly elevated in chimera mice that had received
female FL cells (Figure 4.3H-J, p < 0.05-0.01). Consistent with a female-driven effect
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driving differentiation of mature B cells in the periphery, we found no differences among
the relative levels of pro-B, pre-B and immature B cell subsets in the bone marrow of FL
chimera mice (data not shown).
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Figure 4.3 The female hematopoietic system of (NZB x NZW)F1 mice promotes B
cell differentiation. Spleens were harvested from FL chimera mice at the time of
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sacrifice. Samples were analyzed for the presence of B cell subsets by flow cytometry.
(A-D) Representative plots show the gating strategy used to determine follicular mature
(FO), Marginal Zone (MZ), germinal center (GC), Memory (Mem) B cells and plasma
cells (PC). (E-J) Total numbers of indicated B cell subsets are presented per FL chimera
mouse. Each symbol represents one mouse. * p < 0.05; ** p < 0.01. Brackets in black
indicate statistical differences between groups receiving male or female FL cells, while
brackets in grey represent statistical differences between individual groups of chimeras.
Mice analyzed included female-into-female (n=9, female-into-male (n=11), male-intofemale (n=7) and male-into-male (n=3) FL chimeric mice.
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4.3.4 Autoantibody production is driven by female HCs and not affected by the
presence of male sex hormone
Female (NZB x NZW)F1 mice develop hypergammaglobulinemia at early ages followed
by a specific loss of tolerance to nuclear autoantigens (199,200). We analyzed whether
total immunoglobulin and ANA levels were associated with the sex of the FL donor in
our chimera system. Increased levels of total IgG, IgG1 and IgG2A in the serum of FL
chimera mice did not correlate with the groups of mice developing renal disease (Fig.
4A-C). In fact, male-into-male FL chimera mice, which did not develop lupus-like
disease, had the highest levels of circulating total immunoglobulins. In contrast, the
levels of anti-chromatin IgG, anti-histone IgG and anti-dsDNA IgG were all significantly
elevated in chimera mice that had received female FL cells as compared with those mice
receiving male FL cells (Figure 4.4D-F, p < 0.05-0.001), suggesting that mice that had
received female HCs displayed a specific loss of tolerance to nuclear antigens.
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Figure 4.4 Serum anti-nuclear IgG autoantibody levels in FL chimera (NZB x
NZW)F1 mice are elevated in mice that received female donor cells. Serum total IgG
(A), IgG1 (B), IgG2a (C), anti-chromatin IgG (D), anti-histone IgG (E) and anti-dsDNA
IgG (F) levels were measured by ELISA in samples from FL chimera mice at 12 (A-C)
or 20 (D-F) weeks post irradiation/reconstitution. * p < 0.05; ** p < 0.01; *** p < 0.001.
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Brackets in black indicate statistical differences between groups receiving male or female
FL cells, while brackets in grey represent statistical differences between individual
groups of chimeras. Groups of mice analyzed included female-into-female (n=8–13),
female-into-male (n=11–13), male-into-female (n=7–8) and male-into-male (n=4–8) FL
chimeric mice along with 6–9 female and 6 male unmanipulated age-matched controls.

4.3.5 Levels of serum IFNα, but not BAFF, are elevated in chimera mice receiving
female FL cells
Possibly explanations for this observation include an increased capacity of femalederived B cells to differentiate into autoantibody producing cells or increased levels of B
cell differentiating signals secreted by female-derived non-B cell HCs. To test the later
idea, we examined FL chimera mice for levels of serum B-cell-activating factor (BAFF)
at 16 weeks after irradiation and reconstitution; before the onset of renal disease. B-cellactivating factor (BAFF) is known to be involved in B cell survival and differentiation
and has previously been found to be associated with lupus in several mouse models (1416,246,247). FL chimera mice that had received female HCs did not express elevated
levels of BAFF (Figure 4.5A). In fact, male FL chimera mice were found to express
higher levels of BAFF than female FL chimera mice, regardless of whether these had
received male or female FL cells (p < 0.05).IFNα is also known to influence B cell
differentiation (248) and is capable of driving disease development in (NZB x NZW)F1
mice and related strains (97,236,249,250). We tested serum levels of IFNα in FL
chimera mice 12 weeks post irradiation and reconstitution, before the onset of renal
disease. Mice reconstituted with female FL cells displayed higher levels of serum IFNα
than mice reconstituted with male FL cells (Figure 4.5B, female versus male donor: p <
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0.05). Furthermore, levels of serum IFNα at 12 weeks after transfer correlated
statistically with levels of serum anti-chromatin IgG (p < 0.001), anti-histones IgG (p <
0.05) and anti-dsDNA IgG (p < 0.05) measured 20 weeks after transfer (Figure 4.5C-E).
Serum IFNα levels measured 12 weeks after reconstitution also trended towards a
negative correlation with the onset of renal disease in all FL chimeras (p = 0.1, Figure
4.5F).
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Figure 4.5 Elevated serum IFNα levels are driven by the female hematopoietic
system and correlates with early disease onset. Serum was obtained from FL chimera
mice 12 or 16 week after irradiation and reconstitution. Levels of BAFF were measured
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16 weeks post transfer (A), while levels of IFNα were measured 12 weeks post transfer
(B). Levels of IFNα correlated positively with autoantibody levels at 20 weeks after
irradiation/reconstitution (C-E) and negatively with onset of disease (F). Disease onset
was defined as the time point where any given mouse presented with severe proteinuria
(100 mg/dL) for the first of two consecutive readings (also see Figure 4.2). Each symbol
represents one FL chimera mouse. * p < 0.05. Groups of mice analyzed included femaleinto-female (n= 7-14), female-into-male (n= 8-12), male-into-female (n= 6-8) and maleinto-male (n= 3-8) FL chimeric mice.

4.4 Discussion
Although tremendous amounts of research have gone into determining the
etiology of SLE, the underlying mechanism(s) driving disease initiation and/or
progression are still poorly defined. We and others have previously shown that
manipulation of sex hormone production from puberty significantly alters the
development of renal disease (70,72,73,81,208). Specifically, castration of male lupusprone (NZB x NZW)F1 mice was found to remove the protective effect of testosterone
resulting in disease development equivalent to that of female unmanipulated mice
(70,73). Conversely, ovariectomy of female (NZB x NZW)F1 mice prior to puberty fails
to alter disease kinetics (73,81), suggesting that after the immune system is established
in female mice around 2-3 weeks of age, estrogens are not crucial for disease
progression. Here we have shown that, female HCs are capable of driving lupus-like
disease in hormonally intact, lethally irradiated male (NZB x NZW)F1 FL recipient
mice. Thus, even in the presence of testosterone, female HCs from lupus-prone (NZB x
112

NZW)F1 mice cannot be held back and proceed to generate autoreactive B cells,
followed by IgG-IC deposition, glomerulonephritis and renal failure.

Pre-B cell lines from fetal livers of lupus-prone (NZB x NZW)F1 mice have previously
been shown to possess intrinsic autoimmune competencies when compared with pre-B
cell lines established from non-lupus prone strains (165), however, whether these cells
lines were of a male or female origin was not reported and remains unknown. As the
immune system of FL chimera mice originates from transferred stem cells and progenitor
cells, rather than more mature lymphocytes, our data suggest that the defect is genetically
encoded. A major player in B cell development and differentiation is Bruton’s tyrosine
kinase (Btk) encoded by the X chromosome (251). Although not much is known about
Btk levels and activity in lupus, a recent study reported amelioration of end-stage lupuslike disease in older female (NZB x NZW)F1 mice treated with Btk inhibitor (252). The
study did not investigate if males were equally susceptible, and thus any sex-driven
abnormality remains to be identified. Another candidate gene is Cd40L, also encoded by
the X chromosome. CD40L is essential for T-cell-dependent B-cell activation and has
been

assigned

an

essential

development;(11,253)

however,

role

in

whether

(NZBxNZW)F1
CD40L-mediated

lupus-like
B-cell

disease

activation

is

differentially active in male and female recipients remains unknown.
IFNα is recognized as a key cytokine in SLE and mouse lupus-like disease
(97,101,235,249,250,254). IFNα is predominantly induced in response to viral or
intracellular bacterial infections, but although tempting, a cause-and-effect relationship
between infections and SLE remains elusive. We observed elevated levels of serum IFNα
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in chimera mice that had received female HCs, suggesting that dysregulated IFNα
production, either directly or via exorbitant endogenous stimuli, is also intrinsically
driven by female HCs. Several genes known to be involved in IFNα production and/or
responsiveness have been associated with SLE in genome wide association studies,
including Irf5, Irf7, Irf8, Irak1, Tyk2, Stat4 and Fcgr2a among others (reviewed in
(255)). Of these, Irak1 is particularly interesting. First, the Irak1 gene is encoded on the
X chromosome making it an attractive candidate when studying sex-dependent disease
patterns. Secondly, IRAK1 protein is essential for most TLR-mediated intracellular
signaling resulting in IFNα production. And finally, IRAK1 has been shown to be
required for SLE serum (i.e. IgG-IC)-induced pDC activation and IFNα production (256).

Tlr7 is another X-linked gene that has been strongly associated with mouse lupus-like
disease (234,243), although not directly identified in GWAS studies. Recently, however,
TLR7 expression levels were found to correlate with elevated levels of anti-RNA
antibodies in SLE patients (257). TLR7 is expressed by both pDCs and B cells resulting
in IFNα production and B cell differentiation (94,258), and TLR7-deficient lupus-prone
mice fail to develop significant levels of ANAs (243). Whether female pDCs and/or B
cells respond better to TLR7 cross-linking than male cells remains to be determined,
however, it is tempting to speculate such a relationship since (1) autoantibody producing
CD11c+ B cells depend on TLR7 signaling and are found predominantly in young
autoimmune females (233), and (2) TLR7 agonist stimulation of human PBMCs resulted
in significantly more IFNα production from female, than male cells (259,260).
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As estrogen receptor expression is required for disease development in female (NZB x
NZW)F1 mice, it is interesting to note that IFNα induces transcription of the Esr1 gene
and subsequent expression of the estrogen receptor a (261,262). Oppositely, estrogen
treatment has been suggested to drive dendritic cell activation and enhanced IFNα
production upon TLR ligation (263,264). Whether male and female HCs respond equally
to estrogens has been evaluated both in vivo and in vitro in (NZBxNZW)F1 and nonautoimmune mice, showing no significant differences (264-266). On the basis of these
observations, we do not believe that disease–promoting effect of female HCs is because
of increased responsiveness of female cells to low levels of estrogen present in male
recipients, although further experiments are needed to firmly rule out this possibility.

So what about testosterone and its well established protective effect? We have
recently

described

the

presence

of

a

population

of

testosterone-induced

immunosuppressive myeloid cells (Gr1highCD11b+) in male (NZB x NZW)F1 mice
(211). These cells have the capacity to directly suppress B cell differentiation in vitro,
while depletion in vivo promotes autoantibody production in male mice. In our chimera
system, male recipients experienced a later onset of disease, although autoantibody
production seemed to be only marginally lower in male versus female recipients. On the
basis of these observations, we propose that testosterone may act by promoting the
development of immunosuppressive Gr1highCD11b+ cells capable of delaying, but not
inhibiting, disease development. The presence of these cells is subsequently enough to
control intrinsic disease promoting signals in male HCs, but not in female HCs, the latter
promoting elevated IFNα production, B cell differentiation, ANA production and fatal
renal disease. Taken together, we have found that (NZB x NZW)F1 female HCs have an
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intrinsic ability to drive autoimmune lupus-like disease, regardless of the hormonal
environment of the host. This strongly implicates genetic rather than hormonal factors as
the underlying mechanism driving the increased incidence of autoimmunity in females
as compared to males.
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Chapter V
SUMMARY AND DISCUSSION

1.5.1 Summary of major findings:
The studies in this work are concentrated on delineating the underlying causes for the
strong female sex-bias seen in the (NZBxNZW)F1 mouse model of lupus-like disease.
We have laid emphasis on the effect of sex hormones as well as the genetic factors that
may be responsible for this sex-bias. We have investigated the cellular differences in the
composition of male versus female immune system and have identified key cellular
components playing a critical role in the progression of lupus-like disease in these mice.
Also the relative role of sex hormone versus the intrinsic quality of the hematopoietic
cells is examined using a unique BM chimera system. The major findings are as follows:

1. Male (NZBxNZW)F1 lupus prone mice harbor higher numbers of immunesuppressive Gr1highCD11b+ cells that suppress B cell differentiation in vitro.
2. Antibody mediated depletion of Gr1+ cells only in male (NZBxNZW)F1 leads to
higher levels of auto-antibodies in vivo.
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3. Female Gr1highCD11b+ cells lose suppressor in post-pubertal age and acquire a
stimulatory function as the mice get old.
4. Male and female Gr1highCD11b+ cells use different mechanisms to suppress B cell
differentiation.
5. Antibody mediated depletion of Gr1+ cells only in male (NZBxNZW)F1 leads to
stronger T cell dependent antibody response.
6. Gr1lowCD11b+ cells suppress T cell proliferation in vitro.
7. Depletion of Gr1+ cells leads to more TFH cells and germinal centers.
8. Gr1+ cells suppress TFH cells differentiation in vitro.
9. Hematopoietic cells from female (NZBxNZW) F1 mice can transfer renal disease
to male recipients with higher incidence and faster kinetics.
10. Hematopoietic cells from female (NZBxNZW) F1have disease driving capacity
in utero.
11. Auto-antibody production is controlled by the female hematopoietic cells and not
the host sex hormone levels.
12. BAFF and IFN-α are elevated in recipients of female hematopoietic cells.

To summarize, there are multiple factors driving the lupus-like disease in
(NZBxNZW)F1 mice and we cannot point out a single factor responsible for the sex-bias
observed in the disease. The presence of testosterone driven immune-suppressive
population of Gr1highCD11b+ and Gr1lowCD11b+ in lupus-prone male (NZBxNZW)F1
with specific suppressor function is a novel finding. The elucidation of suppressive
mechanism of male Gr1+CD11b+ can lead to novel therapeutic targets. Also the
dissection of the testosterone dependent generation of Gr1+CD11b+ cells can lead to the
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prospect of enhancing and maintaining these immuo-suppressive cells in female
(NZBxNZW)F1 mice and modulate the progression of lupus-like disease. Testosterone
driven immune-suppressive cells protect from the disease but in the BM chimera system
the female hematopoietic cells take over the protective role of testosterone.

1.5.2 Discussion and future directions:
Sex-bias in autoimmunity is a well-studied and well documented phenomena. Our studies
here try to address the relative contribution of major factors involved in the sex-bias we
see in the (NZBxNZW)F1 mouse model of lupus-like disease such as immune cell
composition, sex-hormones and genetic constitution of the immune system. As the
(NZBxNZW)F1 is a multigenetic and spontaneous mouse model of lupus with a strong
female bias, our findings possibly mimic the actual disease as closely as possible in an
experimental system.

We have recently witnessed the emergence of various regulatory immune cell subsets like
Tregs, Bregs and MDSCs. These regulatory cell types are commonly associated with
immune-suppression which makes them prime targets for therapeutic interventions in
diseases exacerbated by immune dysregulaiton such as autoimmunity and cancer. The
role of Tregs and Bregs has been studied in autoimmune diseases but there are no definitive
studies about their role in lupus. Also the role of MSDCs had been explored in other
autoimmune conditions like EAE and type I diabetes but not in lupus. It is notable is that
the effects of all these regulatory cell types have been studied only in the context of T cell
immunity.
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Our studies in Chapter 2, report a novel immuno-suppressive Gr1highCD11b+ (resembling
granulocytic MDSCs) and Gr1low CD11b+ (resembling monocytic MDSCs) MDSC like
subsets in lupus prone (NZBxNZW) F1 mice. Interestingly, these cells are present in
higher numbers in male (NZBxNZW) F1mice as compared to female (NZBxNZW)
F1mice. It is to be noted that we have shown that the number of MDSC like cells are
regulated by testosterone in (NZBxNZW) F1 mice; but it is not clear that the
functionality of MDSC like cells described here are regulated by testosterone or not. It
has been shown in studies that myeloid progenitors express androgen receptor but we
have not been able to detect androgen receptor expression on myeloid progenitors in the
(NZBxNZW) F1 mouse model. We speculate that BM stromal cells may be responsible
for regulating the number of MDSC like cells in response to testosterone. Further studies
are needed to elucidate the exact mechanism of testosterone mediated regulation of Gr1 +
CD11b+. Additionally, it needs to be addressed that if testosterone affects the Gr1+
CD11b+ cells directly or the effect of testosterone is mediated through a myelopoiesis
promoting cytokine.
We show that Gr1highCD11b+ cells suppress cytokine mediated B cell differentiation in
vitro and that in vivo depletion of Gr1+CD11b+ lead to elevated production of autoantibodies and kidney disease in male (NZBxNZW) F1. Gr1low CD11b+ cells fail to
suppress B cell differentiation indicating the presence of two functionally distinct subsets
of Gr1+CD11B+ expressing cells. The antibody used to deplete Gr1+ CD11b+ cells in vivo
in our studies depletes both Gr1highCD11b+ as well as Gr1low CD11b+ cells, hence we
cannot delineate the in vivo function of the two Gr1 expressing cell sub sets. To examine
the specific role the Gr1highCD11b+ and Gr1low CD11b+ cells in vivo we have to develop a
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system where we can specifically deplete either of the cell population. It is to be noted
that there is a lack of cell surface and morphological markers distinguishing the
functional role of Gr1highCD11b+ and Gr1low CD11b+ cells.

There are contrasting reports regarding the role of MDSC like cells in the pathogenesis of
autoimmune diseases. The cell surface markers defining MDSC like cells (Gr1 and
CD11b) are expressed by neutrophils, monocytes, and macrophages; these cell types are
inflammatory in nature. The pro-inflammatory and disease promoting role of MDSC like
cells in lupus-like disease development cannot be overlooked, but our studies show a
protective role of MDSC like cells in lupus prone (NZBxNZW) F1 male mice. We also
observed that Gr1+CD11b+ cells +acquire an inflammatory phenotype as the female
(NZBxNZW) F1 male mice age. Hence, we speculate the existence of multiple cell
subsets with in the Gr1+CD11b+ cells with specific functionality and regulatory
properties. The lack of cell surface markers and functional assays to determine smaller
cell subsets within the Gr1+ CD11b+ cell population presents a challenge to distinguish
between the immune-suppressive and inflammatory cell types.
Our report is the first showing a direct immune-suppressive effect of Gr1highCD11b+
MDSC like cells on B cells, and that the activity is crucial to the role of Gr1highCD11b+ in
mediating the progression of lupus-like disease in (NZBxNZW) F1 mice as B cells are
the source of pathogenic antibodies. Also the elevated level of serum IL-10 after Gr1+
cell depletion can contribute to the progression of lupus-like disease. The role of IL-10 in
development of autoimmunity is debatable but it has been shown that IL-10 can promote
B cell differentiation. The source of IL-10 producing cells in the absence of Gr1+CD11b+
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is not known and further investigation is required to identify the cellular source of IL-10
in (NZBxNZW) F1 mice. We conducted studies described in Chapter 2 to examine the
role of IL-10 as an immune-suppressive mechanism but our results indicate that IL-10 is
not acting as an immunosuppressant. Finally, the protective role of testosterone in the
development of lupus-like disease in (NZBxNZW) F1 has been well established since the
1970s but the underlying mechanisms are not clear. The regulation of immunesuppressive Gr1+ CD11b+ cells via testosterone may explain, at least in part, the
protective role of testosterone in (NZBxNZW) F1 mice.
Another interesting observation is that the Gr1highCD11b+ cells from female (NZBxNZW)
F1 mice lose their suppressive ability post-pubertaly and hence female mice are
unresponsive to in vivo depletion of Gr1+ cells as the treatments begin at 9-12 weeks of
age. This time period coincides with the increase in female sex hormone (estrogen) levels
and the beginning of disease progression, and chronic inflammation in female
(NZBxNZW) F1 mice. The loss of suppression could be attributed to increased female
sex hormones or the chronic inflammatory milieu present in female (NZBxNZW) F1
mice. As discussed in chapter 1, estrogen has an aggravating effect in driving lupus-like
disease in (NZBxNZW) F1 mice and there is chronic inflammation going on in the form
of elevated IL-6 and IFN-α level in female (NZBxNZW) F1 mice. We therefore cannot
rule out either possibility, but it requires further experiments to firmly establish factors
responsible for loss of suppression by Gr1highCD11b+ cells in post-pubertal female
(NZBxNZW) F1 mice. We should also mention that the Gr1low CD11b+ cells become
stimulatory towards naïve B cells as the mice age which may be due to exposure to
inflammatory cytokines like IFN-α and induction of NETs. Also the Gr1low CD11b+ cells
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are very close to low density granulocytes (LDGs) in cellular morphology and granular
properties, and can further contribute to disease progression in older (NZBxNZW) F1
mice. It has been shown in human studies that NETs act as a source of auto-antigen for
progression of autoimmunity. The loss of immune-suppressive function by female cells
may also be attributed to the intrinsic genetic components of the female immune system.
Further studies are required to explore the loss of immune-suppressive ability of female
cells. Reversing the loss of immune-suppression by female Gr1+CD11b+ cells may be an
attractive target for therapy. Our studies show that the number and function of
Gr1+CD11b+ is differentially regulated in male and female lupus prone mice. These
differences seem to be a combined effect of sex hormones as well as the genetic
properties of the immune system.
The fact that female Gr1highCD11b+ cells use classical suppressive mechanisms (ROS and
iNOS) associated with cancer MDSCs while the male Gr1highCD11b+ cells use an
unknown suppressive mechanism indicates the intrinsic difference in the male and female
Gr1highCD11b+ cells. We have conducted studies aimed at identifying the suppressive
mechanism used my male Gr1highCD11b+ cells. One of the most promising candidate
genes which were found to be upregulated in male Gr1highCD11b+ cells was S100A8/9
(unpublished data). There have been many studies defining the immune-regulatory role of
S100A8/9 proteins on the function and accumulation of MDSCs in cancer models. This
difference may be attributed to the multigenetic nature of (NZBxNZW) F1 mouse model
and needs further investigation. Moreover elucidating the suppressive mechanism used
by male Gr1highCD11b+ cells may present novel therapeutic targets for manipulation in
SLE.
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Another interesting observation is that the proportion of male (NZBxNZW) F1
developing lupus-like disease (~30%) resembles the proportion of male (NZBxNZW) F1
that have relatively lower levels of Gr1+ CD11b+ cells as compared to disease free male
(NZBxNZW) F1 mice. This observation is potentially interesting as the level of these
cells can be used as disease predicting bio-marker in susceptible individuals. There is a
requirement of further studies to examine the possible correlation between Gr1+ CD11b+
cells and development of lupus-like disease in (NZBxNZW) F1 mice.

Since we used a T cell free system to test in vitro suppression of B cell differentiation, the
next question we asked is whether the in vivo effect on antibody secretion is a direct
effect of Gr1+CD11b+ cells on B cells or if it is mediated through T cells. To address this
question we used an immunization approach (described in Chapter 3).

Here we show that female (NZBxNZW) F1 mice respond better to a T dependent
immunization as compared to male (NZBxNZW) F1 mice. This is in line with the fact
that female (NZBxNZW) F1 mice have a hyperactive immune response. Next we showed
that depletion of Gr1+ cells only after immunization with a T cell dependent antigen lead
to a substantially strong antigen-specific immune response in male (NZBxNZW) F1
mice. As observed earlier, the females did not respond to anti-Gr1 treatment. These
findings suggested that in vivo suppression antibody production by Gr1+ cells is
mediated through T cells. The enhanced antigen specific immune response was
accompanied by elevated levels of PCs and GC B cells.
In chapter 1 we described that only Gr1highCD11b+ cells are capable of suppressing B cell
differentiation in vitro; here we found out that only Gr1lowCD11b+ cells were able to
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suppress T cell proliferation in vitro. A similar loss in suppressive function of
Gr1lowCD11b+ cells was observed in the case of older females. Hence, we have
established the specific suppressive role for the two separate Gr1 expressing populations
in lupus-prone (NZBxNZW) F1 male mice. Additionally, both cell subsets lose their
immune-suppressive capability in post-pubertal female (NZBxNZW) F1 mice.
Further, depletion of Gr1+ cells lead to an increase in effector T cell subsets in
immunized animals. As discussed in section 1.5, TFH cells are essential for GC formation
and generation of an antigen-specific antibody mediated immune response. We found that
that Gr1+ cell depletion leads to a rapid increase in TFH cells in vivo after immunization
and correlated with the increase in germinal center B cells. Indeed, we showed that Gr1+
cells can suppress naïve T cell differentiation into TFH cells. Again the suppressive
mechanism used by Gr1+ cells to suppress TFH differentiation remains unknown and
further investigation is required elucidate it.

We can clearly state that testosterone regulated Gr1+ CD11b+ cells paly a protective role
in lupus-prone (NZBxNZW) F1 male mice but they are functionally different in female
(NZBxNZW) F1 mice. We can speculate that these cells have distinct inherent qualities
and affect the progression of lupus-like disease in a different manner.

Genetics is one of the major factors contributing to the sex-bias observed in SLE and
other autoimmune diseases. The hyperactive state of the female immune system and often
X chromosome dosage are responsible for the female predominance in autoimmune
disorders. The studies in Chapter 4 show that the power of female (NZBxNZW) F1 is
enough to overcome the protective role of the testosterone driven immune-suppressive
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Gr1+ CD11b+ population. Testosterone in intact male recipients was only able to mildly
delay the onset of the disease without any effect on the end stage renal disease. The
ability of the female hematopoietic cells to maintain high levels of lupus driving IFN-α
irrespective of the hormonal environment of the host indicates the strong genetic predisposition of the female cells to drive lupus-like disease. In fact, we can speculate that
the immune-suppressive Gr1+ CD11b+ cells can protect lupus prone male (NZBxNZW)
F1 from disease progression due to the lack of a disease driving genetic program, as the
females. Additionally, identification of disease driving cell types in the female
hematopoietic system can also provide therapeutic targets.

To summarize, we can say that the sex-bias in lupus-like disease development in
(NZBxNZW) F1 mice is an outcome of multiple factors. We have identified a
testosterone driven Gr1+ CD11b+ cells immune-suppressive cell population which
protects lupus prone male mice from disease. The female microenvironment comprising
of female sex hormones as well as the pro-inflammatory cytokines may be responsible
for fewer numbers and loss of suppression of Gr1+ CD11b+ cells. Also the differential
function of Gr1+ CD11b+ cells indicates towards an intrinsic difference between male and
female immune system. Also the BM chimera system shows the overpowering role of
female immune system and genetics on the development of lupus-like disease.

Our studies open exciting avenues for therapeutic targets in terms of unknown immunesuppressive mechanism used by male Gr1+CD11b+ cells to regulate lupus like disease
development in (NZBxNZW) F1 mice. Further, elucidation of testosterone mediated
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upregulation of Gr1+CD11b+ cells and the use of Gr1+CD11b+ cell levels as a disease
predictive bio-marker.

Genetics
 X chromosome dosage
 X linked genes (TLRs)
 Higher levels of IFN-α
 Hormone independent ability of
female cells to drive SLE.

Female bias
of
SLE
Sex hormones
 Estrogen promoting
auto reactive B cells
and SLE
 Testosterone promoting
immunosuppressive
MDSC like cells

Regulatory cell
sub-sets
 More MDSC like cells
in males
 Female MDSC like
cells loosing
suppression

Figure 5.1 Relative contribution of different factors in sex-bias of SLE. The strong
female sex-bias seen in SLE is the outcome of multiple factors working together.
Genetics play an important role in the form of X linked gene expression and higher levels
of disease promoting IFN-α production. Sex hormones play another crucial role as
127

estrogen promotes SLE and testosterone has an immune-suppressive function and protect
from SLE. Lastly, we defined immune-suppressive MDSC like Gr1+ cells upregulated in
lupus prone male mice which can further explain the sex-bias observed in SLE.
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